

# BMJ Paediatrics Open

BMJ Paediatrics Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Paediatrics Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjpaedsopen.bmj.com>).

If you have any questions on BMJ Paediatrics Open's open peer review process please email [info.bmjpo@bmj.com](mailto:info.bmjpo@bmj.com)

# BMJ Paediatrics Open

## Transcutaneous Bilirubinometry during and after Phototherapy in Preterm Infants, Prospective Observational Study

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2020-000681
Article Type:	Original research
Date Submitted by the Author:	08-Mar-2020
Complete List of Authors:	Raba, Ali ; Coombe Women and Infants University Hospital O'Sullivan, Anne; Coombe Women and Infants University Hospital, Miletin, Jan; Coombe Women and Infants University Hospital, Paediatric and Newborn Medicine
Keywords:	Jaundice, Neonatology, Monitoring

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Transcutaneous Bilirubinometry during and after Phototherapy in Preterm Infants,**  
4  
5 **Prospective Observational Study**  
6

7 Ali Ahmed Raba<sup>1,2</sup>, Anne O'Sullivan<sup>2</sup>, Jan Miletin<sup>1,2,3,4</sup>  
8  
9

10 <sup>1</sup> UCD School of Medicine and Medical Sciences, Dublin, Ireland  
11

12 <sup>2</sup> Coombe Women and Infants University Hospital, Dublin, Ireland  
13

14 <sup>3</sup> Institute for the Care of Mother and Child, Prague, Czech Republic  
15

16 <sup>4</sup> 3rd School of Medicine, Charles University, Prague, Czech Republic  
17  
18  
19

20 **Short running title:** Transcutaneous Bilirubinometry in Preterm Infants  
21

22 **Corresponding author:** Prof Jan Miletin, MD, FRCPI, FJFICMI  
23

24 **Address:** Coombe Women and Infants University Hospital, Cork Street, Dublin 8, Dublin,  
25  
26  
27 Ireland  
28

29 **Email:** miletinj@yahoo.com  
30

31 **Telephone:** 00353 14085654  
32

33 **Fax:** 00353 14085209  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objective:** To examine the accuracy of Transcutaneous Bilirubinometry (TCB) measurements during and after phototherapy (PTH) in preterm infants

**Design:** Prospective observational cohort study

**Setting:** Level III neonatal centre.

**Patients:** Preterm infants (23<sup>+0</sup> to 36<sup>+6</sup> weeks of gestation) born between June 2017 and May 2018 requiring phototherapy

**Interventions:** TCB was measured from an exposed area of skin, the sternum (TCBU) and covered area of skin under the nappy (TCBC) within an hour of obtaining Total Serum Bilirubin (TSB) samples.

**Main outcome measures:** Correlation and agreement between TCB (TCBU and TCBC) and TSB during and after phototherapy.

**Result:** 196 preterm infants were enrolled. There was a significant correlation between TSB and TCB during PTH ( $r = 0.71$ , 95% CI 0.65 to 0.76 in covered,  $r = 0.75$ , 95% CI 0.70 to 0.79 in uncovered areas) and after PTH ( $r = 0.87$ , 95% CI 0.82 to 0.90). TCB underestimated TSB level during PTH with a mean TCBC-TSB difference of  $-25 \pm 43.4$ , 95% agreement limits of 59 to -109, and a mean TCBU-TSB difference of  $-47.6 \pm 46.3$ , 95% agreement limits of 43 to -138. The agreement between TCB and TSB after cessation of PTH improved, TCB underestimating TSB by a mean TCB-TSB difference of  $-10.3 \pm 31.4$  (95% agreement limits of 51.2 to -71.8).

**Conclusion:** TCB measurements showed a significant correlation with TSB levels in preterm infants during and after phototherapy. TCB was universally underestimating TSB (most significantly on phototherapy in uncovered areas).

**Keywords:** Hyperbilirubinemia, Jaundice, Preterm infants, Transcutaneous bilirubinometry

1  
2  
3  
4  
5 **Abbreviations:** B-A, Bland-Altman; CWIUH, Coombe Women and Infants University  
6 hospital; DCT, direct Coombs test; EOS, early onset sepsis; GIT, gastrointestinal tract; IQR,  
7 interquartile range; mVSD, muscular ventricular septal defect; NICE, National Institute for  
8 Health and Care Excellence; PDA, patent ductus arteriosus; PFO, persistent foramen ovale;  
9 PTH, phototherapy; RDS, respiratory distress syndrome; SD, standard deviation; TCB,  
10 transcutaneous bilirubinometry; TCBC, transcutaneous bilirubinometry reading from covered  
11 skin; TCBU, transcutaneous bilirubinometry reading from uncovered skin; TSB, total serum  
12 bilirubin  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Neonatal hyperbilirubinemia is a very common condition with approximately 50% of term and 80% of preterm infants developing jaundice in the first week of life (1). Hyperbilirubinemia in most cases is benign and self-limiting condition, however, occasionally, severe hyperbilirubinemia can occur and may be associated with irreversible brain damage, especially in preterm infants (2, 3).

Phototherapy (PTH) is considered to be safe and effective treatment for neonatal unconjugated hyperbilirubinemia. The indication to commence treatment is based on the level of serum bilirubin, the age of the baby in hours, and gestational age (4). While appropriate PTH based on the above criteria is safe, aggressive PTH should be ideally avoided as it could reduce the antioxidant effects of moderate bilirubin levels leading to oxidative injury at cell membranes (5, 6).

Measurement of total serum bilirubin (TSB) remains the gold standard for monitoring bilirubin levels during and after PTH in term and preterm infants. However, obtaining heel stick or venous blood samples is painful, time-consuming, and increases the risk of local and systemic infection especially in preterm infants (8). Transcutaneous bilirubinometry (TCB) device works by directing light into the skin of the infant and measuring and analysing the intensity of the returned wavelengths to estimate a TSB (9). TCB has been recommended as a non-invasive, painless and time-saving test for bilirubin estimation in term and late preterm infants prior to the commencement of PTH (10-12).

The use of TCB for infants undergoing PTH is still controversial, some studies reported that PTH has an effect on the correlation between TCB and TSB. While others suggest that TCB readings from covered skin area could be safely used to guide PTH treatment (13, 14). We designed our study to examine the accuracy of TCB to estimate the TSB level in preterm infants undergoing PTH and its reliability after PTH.

## Methods

A single centre prospective observational cohort study performed in the neonatal department of the Coombe Women and Infants University hospital (CWIUH), Dublin, Ireland (level III neonatal centre). All preterm infants (23+0 - 36+6 weeks of gestation) born between June 2017 and May 2018 in CWIUH, who developed significant jaundice requiring PTH, were eligible for enrollment to this study. During the study period, the protocols for screening, diagnosis and management of infants with jaundice were not changed. Infants with clinical or radiological evidence of major congenital anomalies (including those with gastrointestinal tract (GIT) deformities and congenital heart diseases apart from patent ductus arteriosus (PDA), persistent foramen ovale (PFO) and small ( $\leq 5$  mm) muscular ventricular septal defect (mVSD)) were excluded from this study.

PTH was commenced based on TSB levels according to the hospital guidelines taking into account the infant's age in hours and gestation in weeks. Standard PTH units (Photo Therapy 4000, Draeger Medical, Germany) were used. Infants receiving PTH were completely exposed, except for their eyes (covered with a phototherapy goggles for protection) and the nappy area (covered with a disposable nappy). PTH was discontinued when the TSB fell below the relevant treatment threshold.

TCB was measured from uncovered/exposed (TCBU) and covered (TCBC) areas within an hour of obtaining TSB samples. The device was placed over an uncovered area (sternum) and pressed gently against the skin three times to obtain a reading. The process was repeated over the covered area, upper outer quadrant of the buttock (covered by the nappy). After cessation of PTH, TCB's were measured from the sternum. The measurements were obtained by experienced nurses trained and competent in the use of the Dräger Jaundice Meter (JM-105 or JM-103, Draeger Medical, Germany). The TCB devices were calibrated regularly according to the manufacturer's instructions and hospital guidelines. Blood samples for TSB were obtained



1  
2  
3 either by heel prick or venepuncture. The attending neonatologist directed the frequency of  
4  
5 TSB measurements. TSB levels were measured in one clinical laboratory using direct  
6  
7 spectrophotometry. Co-morbidities were recorded during the study period. Confirmed early  
8  
9 onset sepsis (EOS) was defined according to National Institute for Health and Care Excellence  
10  
11 (NICE) guidelines (15), as a positive blood culture bacterial infection within the first three days  
12  
13 of life. PDA was diagnosed on the basis of echocardiographic findings, and it was considered  
14  
15 haemodynamically significant in our study if the measured diameter was greater than 2mm  
16  
17  
18  
19 (16).

20  
21 Our main outcome was to examine the correlation and agreement between TCB (TCBU and  
22  
23 TCBC) and TSB during and after PTH. Our secondary outcomes were to investigate the  
24  
25 influence of gestational age, birth weight, sepsis, respiratory distress syndrome (RDS), PDA  
26  
27 and positive Direct Coombs Test (DCT) on the correlation between TSB and TCB (TCBU and  
28  
29 TCBC) readings during and after PTH.

30  
31 Our prospective cohort study was approved by the Research Ethics Committee of the CWIUH  
32  
33 (Study No.3-2017) and informed written consent was obtained from parents. Patients or the  
34  
35 public were not involved in the design, conduct, or reporting plans of our research.  
36  
37

38  
39 Data were entered into Microsoft Office Excel (MS Excel, Microsoft, USA) and analysed in  
40  
41 SPSS version 24.0. Descriptive statistics were used for all demographic variables of interest  
42  
43 using frequency distribution and percentage for categorical variables. Mean and standard  
44  
45 deviation (SD) were used for parametric numeric data, while non-parametric numeric data were  
46  
47 summarised using median and interquartile range (IQR). Paired Student t-test was used to  
48  
49 compare means. Correlation between TCB (TCBU and TCBC) and TSB was calculated using  
50  
51 Pearson's correlation coefficient during and after phototherapy. Bland-Altman (B-A) analysis  
52  
53 was used to calculate and visualize the agreement between TSB and TCB. We used t-test to  
54  
55 study the influence of gestational age, birth weight, sepsis, RDS, PDA and DCT positivity on  
56  
57  
58  
59  
60

1  
2  
3 the difference between TSB and TCB during and post-phototherapy. Our results were  
4 summarized using p-values and 95% confidence intervals. P-values <0.05 were considered to  
5  
6 be statistically significant.  
7  
8  
9

## 10 11 12 **Results**

13  
14 One hundred and ninety six jaundiced preterm infants, who received phototherapy, were  
15 enrolled to the study. The mean ( $\pm$ SD) gestational age and birth weight of our cohort were 30.4  
16 weeks of gestation ( $\pm$ 3.2) and 1605g ( $\pm$ 638), respectively. The demographic description of our  
17 cohort is presented in the Table 1.  
18  
19

20  
21 There were 328 simultaneous measurements (TSB and TCB) during PTH phase, and 137 pairs  
22 of readings after discontinuation of PTH. The PTH was commenced at mean ( $\pm$ SD) 32.5 ( $\pm$ 20)  
23 hours of life, and the median duration of PTH exposure was 24 hours (IQR 24-32).  
24  
25

26  
27 During PTH phase, the mean TSB  $\pm$ SD (127  $\pm$ 50  $\mu$ mol/L) and mean TCBC  $\pm$ SD (102  $\pm$ 61.6)  
28 were statistically significantly different ( $p$ <0.0001) (Table 2). Similarly, the difference between  
29 the mean TSB  $\pm$ SD (127  $\pm$  50.5  $\mu$ mol/L) and mean TCBU  $\pm$ SD (79.3  $\pm$ 70.4) was statistically  
30 significantly different during PTH ( $p$  <0.0001) (Table 2). Although, there was a significant  
31 correlation between TSB and TCB measurements during PTH ( $r$  =0.71, 95% CI 0.65 to 0.76  
32 from covered,  $r$ = 0.75, 95% CI 0.70 to 0.79 from uncovered areas,  $p$  <0.0001), B-A plots  
33 showed significant bias and imprecisions in the TCB readings. TCB underestimated TSB level  
34 with a mean TCB-TSB difference of -25  $\pm$ 43.4 from covered area (95% agreement limits of  
35 59.2 to -109,  $p$  <0.0001) and of -47.6  $\pm$ 46.3 from uncovered area (95% agreement limits of 43  
36 to -138,  $p$  <0.0001) (Figure 1, Figure 2).  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53  
54 During post-phototherapy phase, TSB  $\pm$ SD (152  $\pm$ 51.2  $\mu$ mol/L) and TCB  $\pm$ SD (142  $\pm$ 62.8)  
55 measurements were statistically significantly different ( $p$ <0.0001) (Table 3). After cessation of  
56 PTH, the correlation between TCB and TSB further improved ( $r$  =0.87, 95% CI 0.82-0.9,  $p$   
57  
58  
59  
60

1  
2  
3 <0.0001) (Figure 3A). B-A plot showed also an improvement in the agreement between TCB  
4 and TSB, but TCB continued to underestimate of TSB level by  $-10.3 \pm 31.4$  (95% agreement  
5 limits of 51.2 to -71.8,  $p < 0.0001$ ) (Figure 3B).  
6  
7

8  
9  
10 We determined that gestational age, birth weight, sepsis, RDS, PDA and DCT positivity had  
11 no influence on the mean difference between the TSB and TCB (TCBU and TCBC) readings  
12 during the PTH (Table 4). We found also that the difference between the TSB and TCB  
13 measurements after the phototherapy were not affected by gestational age, birth weight, PDA,  
14 DCT positivity. However, infants with a diagnosis of RDS had a statistically significant  
15 reduction in the difference between TCB and TSB, in comparison to those infants without RDS,  
16 after cessation the PTH (Table 5).  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

## 28 Discussion

29  
30 Our study revealed a significant correlation between the TCB and TSB during and after  
31 phototherapy in preterm infants. However, our findings showed a significant wide  
32 disagreement between TCB and TSB measurements during PTH phase. Although, TCB  
33 readings from the covered skin had better agreement than those from the exposed skin, TCB  
34 measurements were associated with a large bias during PTH. We noted that the TCB device  
35 could underestimate serum bilirubin level by up to 109 and 138  $\mu\text{mol/L}$ , from covered and  
36 uncovered area, respectively, during phototherapy.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 In general, the significant correlation between TCB and TSB during PTH is consistent with the  
48 findings in some previous studies in preterm infants. Cucuy (17) et al conducted a study of 86  
49 preterm infants with a mean gestational age of 32 weeks and a mean birth weight of 1637g.  
50 Although they found a good correlation between TSB and TCB during PTH ( $r = 0.8$ ), it was not  
51 clear if their TCB readings were measured from the exposed or covered skin during  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 phototherapy. In addition to this, they did not provide information about the level of agreement  
4  
5 between the TCB and TSB measurements.  
6

7  
8 There are only a few studies that examined 95% agreement limits between the TCB and TSB  
9  
10 in preterm infants during phototherapy. Nagar et al (18) performed a smaller study on 90  
11  
12 preterm infants with a mean gestational age of 32.4 weeks and a mean birth weight of 1847g.  
13  
14 They found that TCB cannot be recommended for the bilirubin measurement during PTH in  
15  
16 preterm infants due to the high risk of underestimation of TSB by up to 132 and 157  $\mu\text{mol/L}$   
17  
18 from covered and uncovered skin, respectively. Although, their sample was smaller and infants  
19  
20 older than our cohort, their results were quite comparable to our findings.  
21  
22

23  
24 Zecca et al (19) conducted a study on 364 preterm and term infants requiring phototherapy.  
25  
26 The mean gestational age and the mean birth weight of their sample were of 34.6 weeks of  
27  
28 gestation and 2371g, respectively, which were more than the mean gestational age and the  
29  
30 mean birth weight of our cohort. They reported a smaller bias between TCB readings from  
31  
32 covered skin and TSB compared to our results. Their results demonstrated that TCB from  
33  
34 exposed skin underestimated TSB by  $54 \pm 51 \mu\text{mol/L}$ , while TCB from covered skin  
35  
36 underestimated TSB by  $3.1 \pm 53 \mu\text{mol/L}$ . However, B-A plots showed a wide TCB-TSB  
37  
38 disagreement with a risk of underestimation of TSB by up to 106  $\mu\text{mol/L}$  from covered skin  
39  
40 and 153  $\mu\text{mol/L}$  from exposed skin.  
41  
42  
43

44  
45 We have shown that the TCB readings from both covered and uncovered area were lower than  
46  
47 TSB levels. Immaturity of the skin and the absence of subcutaneous fat in preterm infants  
48  
49 which leads to rapid clearance of bilirubin levels from the skin following initiation of PTH may  
50  
51 be an explanation (10, 20). This however would contravene the findings of DeLuca et al who  
52  
53 reported that TCB reading from covered skin and TSB correlated strongly ( $r = 0.84$ ,  $p < 0.001$ )  
54  
55 in their study of 60 extremely preterm infants undergoing phototherapy and, unlike our finding,  
56  
57 TCB overestimated TSB with a mean TCB-TSB difference of  $47.8 \pm 41 \mu\text{mol/L}$  (21).  
58  
59  
60

1  
2  
3 During the post-phototherapy phase, our data revealed a better correlation between TCB and  
4 TSB reading ( $r=0.87$ ) as compared to that during PTH phase ( $r=0.7$ ). Moreover, there was a  
5 significant improvement in the agreement between TCB and TSB after cessation of the PTH.  
6  
7 TCB underestimated of TSB only by  $-10.3 \pm 31.4$  with 95% agreement limits of 51.2 to -71.8.  
8  
9 The level of underestimation of TCB observed here are similar to those observed in Nagar et  
10  
11 al study (18).  
12  
13

14  
15 The strength of our study is that it is a large prospective observational study that enrolled not  
16  
17 only healthy preterm infants, but also sick and ventilated premature infants. Another notable  
18  
19 strength is that the number of paired TCB-TSB measurements was large in comparison to  
20  
21 previous studies. Additionally, the possible risk factors that could affect the correlation  
22  
23 between TCB-TSB readings were examined. Finally, we provided recent data for the  
24  
25 agreement between TCB and TSB which is more helpful in clinical practice than correlation  
26  
27 coefficient. Thus, our study added significant findings to the limited literature on the use of the  
28  
29 TCB device in preterm infants during and after phototherapy.  
30  
31  
32

33  
34 The present study has some limitations. Firstly, we did not examine the effect of the duration  
35  
36 and recommencement of PTH on the TSB-TCB correlation. Also, TCB was only measured  
37  
38 from exposed skin (sternum) after PTH was discontinued, and the TCB measurements from  
39  
40 covered area (nappy area) could have different correlation and agreement with TSB.  
41  
42  
43

44  
45 In conclusion, TCB measurements correlate strongly with TSB levels during and after  
46  
47 phototherapy. However, as result of the wide disagreement between TCB and TSB  
48  
49 measurements during PTH phase, TCB device cannot be recommended for monitoring  
50  
51 bilirubin level during phototherapy. However, TCB should be used to estimate the bilirubin  
52  
53 level post-phototherapy.  
54  
55  
56  
57

58 **Acknowledgement:** The authors would like to thank all babies and families who  
59  
60

1  
2  
3 participated in this study along with medical and midwifery staff at the CWIUH.  
4  
5  
6  
7

8 **Contributors:** Dr. Raba designed the study, contributed substantially to the data collection and  
9  
10 analysis and drafted the initial manuscript. Ms. O’Sullivan contributed substantially to the data  
11  
12 collection and analysis and reviewed and revised the manuscript. Prof Miletin conceptualised  
13  
14 and designed the study, supervised the conduct of the study and coordinated the data analysis.  
15  
16 He reviewed and revised the manuscript critically for important intellectual content. All the  
17  
18 authors approved the final manuscript as submitted. They agree to be accountable for all aspects  
19  
20 of the work.  
21  
22  
23  
24  
25

26 **Compliance with Ethical Statements:**  
27

28 **Conflict of Interest:** The authors declare that they have no conflict of interest  
29

30 **Ethical approval:** The Research Ethics Committee of the Coombe Women and Infants  
31  
32 University Hospital approved the study (Study No.3-2017)  
33  
34

35 **Informed consent:** Informed written consent was obtained from all participants  
36  
37

38 **Funding:** Dr Raba work was supported by the grant from Department of Cultural Affairs,  
39  
40 Libya (Ref: HG6-490-45693) (managed by University College Dublin)  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### What is already known on this topic?

- Transcutaneous Bilirubinometry (TCB) is a non-invasive test used as a validated screening tool for hyperbilirubinemia in term infants
- The accuracy of TCB measurement during phototherapy is still controversial in term and preterm infants
- Few studies reported that TCB measurement from covered skin during phototherapy could provide more accurate approximations of total serum bilirubin level in term infants

### What this study adds?

- Transcutaneous Bilirubinometry (TCB) measurements correlates significantly with Total Serum Bilirubin (TSB) levels in preterm infants during and after phototherapy
- TCB underestimates TSB with a significant wide disagreement between TCB and TSB measurements during phototherapy in preterm infants making it unreliable despite significant correlation
- The TCB should be used for TSB estimation post-phototherapy due to significant correlation and improved and clinically acceptable agreement between TCB and TSB

## References

1. Woodgate P, Jardine LA. Neonatal jaundice. *BMJ Clin Evid*. 2011;15.
2. Watchko JF, Oski FA. Kernicterus in preterm newborns: past, present, and future. *Pediatrics*. 1992;90(5):707-15.
3. Cashore WJ. The neurotoxicity of bilirubin. *Clin Perinatol*. 1990;17(2):437-47.
4. Mitra S, Rennie J. Neonatal jaundice: aetiology, diagnosis and treatment. *Br J Hosp Med (Lond)*. 2017;78(12):699-704.
5. Tozzi E, Tozzi-Ciancarelli MG, Di Giulio A, D'Alfonso A, Farello G, Spennati GF, et al. In vitro and in vivo effects of erythrocyte phototherapy on newborns. *Biol Neonate*. 1989;56(4):204-9.
6. Morris BH, Oh W, Tyson JE, Stevenson DK, Phelps DL, O'Shea TM, et al. Aggressive vs. conservative phototherapy for infants with extremely low birth weight. *N Engl J Med*. 2008;359(18):1885-96.
7. Tyson JE, Pedroza C, Langer J, Green C, Morris B, Stevenson D, et al. Does aggressive phototherapy increase mortality while decreasing profound impairment among the smallest and sickest newborns? *J Perinatol*. 2012;32(9):677-84.
8. Badiie Z, Mohammadzadeh M, Shamee M. Diagnostic usefulness of transcutaneous bilirubinometry in very preterm newborns. *Int J Prev Med*. 2012;3(4):262-5.
9. Ahmed M, Mostafa S, Fisher G, Reynolds TM. Comparison between transcutaneous bilirubinometry and total serum bilirubin measurements in preterm infants <35 weeks gestation. *Ann Clin Biochem*. 2010;47(Pt 1):72-7.
10. Ozkan H, Oren H, Duman N, Duman M. Dermal bilirubin kinetics during phototherapy in term neonates. *Acta Paediatr*. 2003;92(5):577-81.



- 1  
2  
3 11. Beck M, Kau N, Schlebusch H. Transcutaneous bilirubin measurement in newborn  
4 infants: evaluation of a new spectrophotometric method. *Arch Dis Child Fetal Neonatal Ed.*  
5  
6 2003;88(4):F350-1.  
7
- 8  
9  
10 12. Nagar G, Vandermeer B, Campbell S, Kumar M. Effect of Phototherapy on the  
11 Reliability of Transcutaneous Bilirubin Devices in Term and Near-Term Infants: A Systematic  
12 Review and Meta-Analysis. *Neonatology.* 2016;109(3):203-12.  
13  
14
- 15 13. Tan KL, Dong F. Transcutaneous bilirubinometry during and after phototherapy. *Acta*  
16  
17 *Paediatr.* 2003;92(3):327-31.  
18  
19
- 20 14. Rylance S, Yan J, Molyneux E. Can transcutaneous bilirubinometry safely guide  
21 phototherapy treatment of neonatal jaundice in Malawi? *Paediatr Int Child Health.*  
22 2014;34(2):101-7.  
23  
24
- 25 15. Caffrey Oswald E PP. NICE clinical guideline: antibiotics for the prevention and  
26 treatment of early-onset neonatal infection. 2014.  
27  
28
- 29 16. Evans N. Diagnosis of patent ductus arteriosus in the preterm newborn. *Arch Dis Child.*  
30 1993;68(1 Spec No):58-61.  
31  
32
- 33 17. Cucuy M, Juster-Reicher A, Flidel O, Shinwell E. Correlation between transcutaneous  
34 and serum bilirubin in preterm infants before, during, and after phototherapy. *J Matern Fetal*  
35 *Neonatal Med.* 2018;31(10):1323-6.  
36  
37
- 38 18. Nagar G, Kumar M. Effect of phototherapy on the diagnostic accuracy of  
39 transcutaneous bilirubin in preterm infants. *Journal of Clinical Neonatology.* 2017;6(3):148-  
40 53.  
41  
42
- 43 19. Zecca E, Barone G, De Luca D, Marra R, Tiberi E, Romagnoli C. Skin bilirubin  
44 measurement during phototherapy in preterm and term newborn infants. *Early Hum Dev.*  
45 2009;85(8):537-40.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 20. Kanti V, Bonzel A, Stroux A, Proquitte H, Buhner C, Blume-Peytavi U, et al. Postnatal  
4 maturation of skin barrier function in premature infants. *Skin Pharmacol Physiol.*  
5  
6 2014;27(5):234-41.  
7  
8  
9  
10 21. De Luca D, Dell'Orto V. Patched Skin Bilirubin Assay to Monitor Neonates Born  
11  
12 Extremely Preterm Undergoing Phototherapy. *J Pediatr.* 2017;188:122-7.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1**  
**Baseline population Characteristics**

Variable	Number
Male Sex n (%)	105 (53.6%)
Birth Weight (grams) Mean $\pm$ SD	1605 $\pm$ 638
Gestational age (weeks) Mean $\pm$ SD	30.4 $\pm$ 3.2
Mode of Delivery n (%)	
NVD	56 (28.6%)
Instrumental Delivery	3 (1.5%)
Elective LSCS	59 (30.1%)
Emergency LSCS	78 (39.8%)
Apgar score at 1 <sup>st</sup> minute Median (IQR)	7 (5-9)
Apgar score at 5 <sup>th</sup> minute Median (IQR)	9 (8-10)
Blood group infants (when done) n (%)	175 (89%)
A	48 (27.4%)
B	18 (10.2%)
AB	2 (1%)
O	108 (61.7%)
Rhesus +	150/175 (85.7%)
Maternal group n (%)	
A	60 (30.6%)
B	24 (12.2%)
AB	5 (2.6%)
O	104 (53.1%)
Rhesus +	176 (89.9%)
Positive DCT n (%)	7 (3.6%)
Maternal age (years) Mean $\pm$ SD	32 $\pm$ 6.2
Proven EOS n (%)	5 (2%)
Antibiotics treatment n (%)	145 (74%)

NVD, normal vaginal delivery; DCT, direct Coombs test; LSCS, lower segment Caesarean section; EOS, early onset sepsis

**Table 2**  
**Paired samples of TSB and TCB from covered and uncovered skin during phototherapy**

		$\mu\text{mol/l}$ , mean (SD)	N	P-value
During PTH	TCBC	102 (61.6)	299	<0.0001
	TSB	127 (50.5)	299	
During PTH	TCBU	79.3 (70.4)	309	<0.0001
	TSB	126.9 (50.9)	309	

TSB, total serum bilirubin; TCBC, Transcutaneous bilirubinometry readings from covered skin; TCBU, Transcutaneous bilirubinometry readings from exposed skin; PTH, phototherapy

**Table 3**  
**Paired samples of TSB and TCB from uncovered skin post-phototherapy**

		$\mu\text{mol/l}$ , mean (SD)	N	P-value
After PTH	TCB	142 (62.8)	137	<0.0001
	TSB	153 (51.2)	137	

TSB, total serum bilirubin; TCB, Transcutaneous bilirubinometry; PTH, phototherapy

**Table 4**  
**The influence of EOS, PDA, RDS and positive DCT on the difference between TSB and TCB during phototherapy**

	Difference between mean TSB and mean TCBC $\pm$ SD ( $\mu$ mol/l)	P-value	Difference between mean TSB and mean TCBU $\pm$ SD ( $\mu$ mol/l)	P-value
<b>EOS</b>				
Yes	21.9 $\pm$ 39.5	0.258	49.2 $\pm$ 42.4	0.064
No	18 $\pm$ 31.8		58.6 $\pm$ 30.7	
<b>PDA</b>				
Yes	32.6 $\pm$ 34.4	0.642	67.1 $\pm$ 34.1	0.28
No	19.16 $\pm$ 37.8		49 $\pm$ 40.2	
<b>RDS</b>				
Yes	22.3 $\pm$ 37.9	0.627	48.2 $\pm$ 38.1	0.246
No	16.5 $\pm$ 36.1		65.2 $\pm$ 43.4	
<b>DCT</b>				
Positive	3.5 $\pm$ 20	0.181	27 $\pm$ 43	0.645
Negative	21 $\pm$ 38.8		52.6 $\pm$ 40.3	

EOS, early onset sepsis; DCT, direct coombs test; PDA, patent ductus arteriosus; RDS, respiratory distress syndrome; TSB, total serum bilirubin; TCB, Transcutaneous bilirubinometry; TCBC, Transcutaneous bilirubinometry from covered area when on phototherapy; TCBU, Transcutaneous bilirubinometry from exposed area when on phototherapy

**Table 5**  
**The influence of EOS, PDA, RDS and positive DCT on the difference between TSB and TCB post-phototherapy**

	<b>Difference between mean TSB and mean TCB <math>\pm</math>SD (<math>\mu</math>mol/l)</b>	<b>P-value</b>
<b>EOS</b>		
Yes	7.9 $\pm$ 32.2	0.637
No	16.3 $\pm$ 31.2	
<b>PDA</b>		
Yes	13.8 $\pm$ 34.3	0.623
No	9.4 $\pm$ 31.6	
<b>RDS</b>		
Yes	9 $\pm$ 33.8	0.024
No	15.9 $\pm$ 22.4	
<b>DCT</b>		
positive	5.3 $\pm$ 43.7	0.349
negative	10.9 $\pm$ 31.5	

EOS, early onset sepsis; DCT, direct coombs test; PDA, patent ductus arteriosus; RDS, respiratory distress syndrome; TSB, total serum bilirubin; TCB, Transcutaneous bilirubinometry

## Legends

### Figure 1A

Correlation between Total Serum Bilirubin (TSB) and Transcutaneous Bilirubinometry (TCB) from covered skin during phototherapy

### Figure 1B

B–A plot showing the 95% limits of agreement between TCB from covered skin and TSB during phototherapy

### Figure 2A

Correlation between Total Serum Bilirubin (TSB) and Transcutaneous Bilirubinometry (TCB) from uncovered skin during phototherapy

### Figure 2B

B–A plot showing the 95% limits of agreement between TCB from uncovered skin and TSB during phototherapy


### Figure 3A

Correlation between Total Serum Bilirubin (TSB) and Transcutaneous Bilirubinometry (TCB) after phototherapy

### Figure 3B

B–A plot showing the 95% limits of agreement between TCB and TSB after phototherapy


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



297x210mm (600 x 600 DPI)




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



297x210mm (600 x 600 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



297x209mm (300 x 300 DPI)

# BMJ Paediatrics Open

## Transcutaneous Bilirubinometry during and after Phototherapy in Preterm Infants, Prospective Observational Study

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2020-000681.R1
Article Type:	Original research
Date Submitted by the Author:	01-May-2020
Complete List of Authors:	Raba, Ali ; Coombe Women and Infants University Hospital O'Sullivan, Anne; Coombe Women and Infants University Hospital, Miletin, Jan; Coombe Women and Infants University Hospital, Paediatric and Newborn Medicine
Keywords:	Jaundice, Neonatology, Monitoring

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Transcutaneous Bilirubinometry during and after Phototherapy in Preterm Infants,**  
4  
5 **Prospective Observational Study**  
6

7 Ali Ahmed Raba<sup>1,2</sup>, Anne O'Sullivan<sup>2</sup>, Jan Miletin<sup>1,2,3,4</sup>  
8  
9

10 <sup>1</sup> UCD School of Medicine and Medical Sciences, Dublin, Ireland  
11

12 <sup>2</sup> Coombe Women and Infants University Hospital, Dublin, Ireland  
13

14 <sup>3</sup> Institute for the Care of Mother and Child, Prague, Czech Republic  
15

16 <sup>4</sup> 3rd School of Medicine, Charles University, Prague, Czech Republic  
17  
18  
19

20 **Short running title:** Transcutaneous Bilirubinometry in Preterm Infants  
21

22 **Corresponding author:** Prof Jan Miletin, MD, FRCPI, FJFICMI  
23

24 **Address:** Coombe Women and Infants University Hospital, Cork Street, Dublin 8, Dublin,  
25  
26  
27 Ireland  
28

29 **Email:** miletinj@yahoo.com  
30

31 **Telephone:** 00353 14085654  
32

33 **Fax:** 00353 14085209  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objective:** To examine the accuracy of Transcutaneous Bilirubinometry (TCB) measurements during and after phototherapy (PT) in preterm infants

**Design:** Prospective observational cohort study

**Setting:** Level III neonatal centre.

**Patients:** Preterm infants ( $23^{+0}$  to  $36^{+6}$  weeks of gestation) born between June 2017 and May 2018 requiring PT

**Interventions:** TCB was measured from an exposed area of skin (the sternum, (TCBU)) and covered area of skin under the nappy (the bony part of the upper outer quadrant of the buttock (TCBC)) within an hour of obtaining Total Serum Bilirubin (TSB)

**Main outcome measures:** Correlation and agreement between TCB (TCBU and TCBC) and TSB during and after phototherapy

**Result:** We have enrolled 196 preterm infants. There was a significant correlation between TSB and TCB during PT ( $r = 0.72$ , 95% CI 0.66 to 0.77 in covered,  $r = 0.75$ , 95% CI 0.70 to 0.80 in uncovered areas) and after PT ( $r = 0.87$ , 95% CI 0.83 to 0.91). TCB underestimated TSB level during PT with a mean TCBC-TSB difference of  $-25 \pm 43$ , 95% agreement limits of 62 to -112, and a mean TCBU-TSB difference of  $-48 \pm 46$ , 95% agreement limits of 45 to -140. The agreement between TCB and TSB after cessation of PT improved, TCB underestimating TSB by a mean TCB-TSB difference of  $-10 \pm 31$  (95% agreement limits of 52 to -72).

**Conclusion:** TCB measurements correlated strongly with TSB levels during and after phototherapy. However, there was a wide and clinically relevant disagreement between TCB and TSB measurements during PT phase, improving significantly post PT.

**Keywords:** Hyperbilirubinemia, Jaundice, Preterm infants, Transcutaneous bilirubinometry

1  
2  
3 **Abbreviations:** B-A, Bland-Altman; CWIUH, Coombe Women and Infants University  
4 hospital; DCT, direct Coombs test; EOS, early onset sepsis; GIT, gastrointestinal tract; IQR,  
5 interquartile range; mVSD, muscular ventricular septal defect; NICE, National Institute for  
6 Health and Care Excellence; PDA, patent ductus arteriosus; PFO, persistent foramen ovale;  
7  
8 PT, phototherapy; RDS, respiratory distress syndrome; SD, standard deviation; TCB,  
9 transcutaneous bilirubinometry; TCBC, transcutaneous bilirubinometry reading from covered  
10 skin; TCBU, transcutaneous bilirubinometry reading from uncovered skin; TSB, total serum  
11 bilirubin  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Neonatal hyperbilirubinemia is a very common condition with approximately 50% of term and 80% of preterm infants developing jaundice in the first week of life (1). Hyperbilirubinemia in most cases is a benign and self-limiting condition, however severe hyperbilirubinemia can occasionally occur and may be associated with irreversible brain damage, especially in preterm infants (2, 3).

Phototherapy (PT) is considered to be a safe and effective treatment for neonatal unconjugated hyperbilirubinemia. The indication to commence treatment is based on the level of serum bilirubin, the age of the baby in hours, and gestational age (4). Evidence is conflicting regarding the best therapeutic approach to hyperbilirubinemia, especially in extremely low birth weight (ELBW) infants. A randomised clinical trial (RCT) performed by the Neonatal Research Network found no significant difference in the rate of death or neurodevelopmental impairment at 18 to 22 months corrected age in ELBW infants who received aggressive PT versus those who received conservative PT. However, aggressive PT was associated with a reduction in the rate of neurodevelopmental impairment alone.(5) However, the post hoc analysis showed that in the smallest and sickest subgroup (mechanically ventilated infants with birth weight less than 750g), aggressive PT may increase mortality while reducing neurodevelopmental impairment.(6)

Measurement of total serum bilirubin (TSB) remains the gold standard for monitoring bilirubin levels during and after PT in term and preterm infants. However, obtaining heel stick or venous blood samples is painful, time-consuming, and increases the risk of local and systemic infection especially in preterm infants (7). A transcutaneous bilirubinometry (TCB) device works by directing light into the skin of the infant and measuring and analysing the intensity of the returned wavelengths to estimate a TSB (8). TCB has been recommended as a non-invasive, painless and time-saving test for bilirubin estimation in term and late preterm infants prior to



1  
2  
3 the commencement of PT (9-11). However, TCB measurements are not recommended in the  
4  
5 first 24 hours of life or in preterm infants below 35 weeks of gestation according to the National  
6  
7 Institute for Clinical Excellence (NICE) guidelines. (12)  
8  
9  
10 (<https://www.nice.org.uk/guidance/cg98>).

11  
12 Despite the NICE guidelines, it seems that TCB has strong correlation and acceptable  
13  
14 agreement in preterm infants before phototherapy.(13, 14) The use of TCB for infants during  
15  
16 and after PT is still controversial, as some studies reported that PT blanches the skin thereby  
17  
18 affecting the correlation between TCB and TSB during and after phototherapy(15) while others  
19  
20 suggest that TCB readings from covered skin area could be safely used to guide treatment  
21  
22 during and post PT.(16-18). We designed our study to examine the accuracy of TCB to estimate  
23  
24 the TSB level in preterm infants undergoing PT and its reliability after PT.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Methods

A single centre prospective observational cohort study performed in the neonatal department of the Coombe Women and Infants University hospital (CWIUH), Dublin, Ireland (level III neonatal centre). All preterm infants (23+0 - 36+6 weeks of gestation) born between June 2017 and May 2018 in CWIUH who developed significant jaundice requiring PT were eligible for enrollment to this study. During the study period, the protocols for screening, diagnosis and management of infants with jaundice were not changed. Infants with clinical or radiological evidence of major congenital anomalies (including those with gastrointestinal tract (GIT) deformities and congenital heart diseases apart from patent ductus arteriosus (PDA), persistent foramen ovale (PFO) and small ( $\leq 5$  mm) muscular ventricular septal defect (mVSD)) were excluded from this study.

PT was commenced based on TSB levels according to the hospital guidelines, taking into account the infant's age in hours and gestation in weeks. The NICE treatment charts were used for preterm infants below 32 weeks of gestation (Appendix 1). In infants  $\geq 32$  weeks of gestation, a chart adapted from the National Health Service (NHS), Glasgow, UK was used (Appendix 2). Standard PT units (Photo Therapy 4000, Draeger Medical, Germany) were used (overhead PT microlight units deliver  $\geq 10$   $\mu\text{W}/\text{cm}^2/\text{nm}$  and Halogen spotlights which can deliver 20-25  $\mu\text{W}/\text{cm}^2/\text{nm}$ ). Infants receiving PT were completely exposed, except for their eyes (covered with phototherapy goggles for protection) and the nappy area (covered with a disposable nappy). PT was discontinued when the TSB fell below the relevant treatment threshold.

TCB was measured from uncovered/exposed (TCBU) and covered (TCBC) areas within an hour of obtaining TSB samples. The device was placed over an uncovered area (sternum) and pressed gently against the skin three times to obtain one reading (the average of the three measured values). The process was repeated over the covered area, the bony part of the upper

1  
2  
3 outer quadrant of the buttock (covered by the nappy). After cessation of PT, TCB's were  
4  
5 measured from the sternum. The measurements were obtained by experienced nurses trained  
6  
7 and competent in the use of the Dräger Jaundice Meter (JM-105 or JM-103, Draeger Medical,  
8  
9 Germany). The TCB devices were calibrated regularly according to the manufacturer's  
10  
11 instructions and hospital guidelines. Blood samples for TSB were obtained either by heel prick  
12  
13 or venepuncture. The attending neonatologist directed the frequency of TSB measurements.  
14  
15 TSB levels were measured in one clinical laboratory using direct spectrophotometry (Abbot  
16  
17 Architect C8000, Abbott, USA). Co-morbidities were recorded during the study period.  
18  
19 Confirmed early onset sepsis (EOS) was defined according to National Institute for Health and  
20  
21 Care Excellence (NICE) guidelines (19) as a positive blood culture bacterial infection within  
22  
23 the first three days of life.

24  
25  
26 Our primary outcome was the correlation and agreement between TCB (TCBU and TCBC)  
27  
28 and TSB during and after PT.

29  
30  
31 Our prospective cohort study was approved by the Research Ethics Committee of the CWIUH  
32  
33 (Study No.3-2017) and informed written consent was obtained from parents. Patients or the  
34  
35 public were not involved in the design, conduct, or reporting plans of our research.

36  
37  
38 Data was entered into Microsoft Office Excel (MS Excel, Microsoft, USA) and analysed by  
39  
40 the StatsDirect v.3.2.10 software (StatsDirect Ltd, UK). Descriptive statistics were used for all  
41  
42 demographic variables of interest using frequency distribution and percentage for categorical  
43  
44 variables. Mean and standard deviation (SD) were used for normally distributed data, while  
45  
46 non normal distribution data was summarised using median and interquartile range (IQR).  
47  
48 Paired-samples t-test was used to compare TCB and TSB paired measurements. When the  
49  
50 differences between pairs were not normally distributed, we used the Wilcoxon signed-rank  
51  
52 test for two sample comparisons. For non-dependent variables we have used an unpaired t-test  
53  
54 or Mann-Whitney U test as appropriate. Correlation between TCB (TCBU and TCBC) and  
55  
56  
57  
58  
59  
60

1  
2  
3 TSB was calculated using Pearson's correlation coefficient during and after phototherapy.  
4  
5 Bland-Altman (B-A) analysis was used to calculate and visualize the agreement between TSB  
6  
7 and TCB. The agreement limits are demonstrated as a 95% confidence interval (95% CI =  
8  
9 mean  $\pm$  1.96 standard deviations), where the ideal agreement difference between measurements  
10  
11 is zero. Our results were summarized using p-values and 95% confidence intervals. P-values  
12  
13  $<0.05$  were considered to be statistically significant. We have used a convenience sample for  
14  
15 the study with planned one year enrolment.  
16  
17  
18  
19  
20  
21

## 22 **Results**

23  
24 One hundred and ninety six jaundiced preterm infants who received phototherapy were  
25  
26 enrolled to the study. The mean ( $\pm$ SD) gestational age and birth weight of our cohort were 30.4  
27  
28 weeks of gestation ( $\pm$ 3.2) and 1605g ( $\pm$ 638), respectively. The demographic description of our  
29  
30 cohort is presented in the Table 1.  
31

32  
33 There were 328 simultaneous measurements (TSB and TCB) during the PT phase and 142 pairs  
34  
35 of readings after discontinuation of PT. The PT was commenced at mean ( $\pm$ SD) 32.5 ( $\pm$ 20)  
36  
37 hours of life and the median duration of PT exposure was 24 hours (IQR 24-32).  
38

39  
40 During the PT phase, the mean TSB  $\pm$ SD (127  $\pm$ 51  $\mu$ mol/L) and mean TCBC  $\pm$ SD (102  $\pm$ 62)  
41  
42 were statistically significantly different ( $p < 0.0001$ ) (Table 2). Similarly, the difference between  
43  
44 the mean TSB  $\pm$ SD (127  $\pm$ 51  $\mu$ mol/L) and mean TCBU  $\pm$ SD (79  $\pm$ 70) was statistically  
45  
46 significantly different during PT ( $p < 0.0001$ ) (Table 2). Although there was a significant  
47  
48 correlation between TSB and TCB measurements during PT, ( $r = 0.72$ , 95% CI 0.66 to 0.77  
49  
50 from covered,  $r = 0.75$ , 95% CI 0.70 to 0.80 from uncovered areas,  $p < 0.0001$ ), B-A plots  
51  
52 showed significant bias and imprecisions in the TCB readings. TCB underestimated TSB level  
53  
54 with a mean TCB-TSB difference of  $-25 \pm 43$  from covered area (95% agreement limits of 62  
55  
56  
57  
58  
59  
60

1  
2  
3 to -112,  $p < 0.0001$ ) and of  $-48 \pm 46$  from uncovered area (95% agreement limits of 45 to -140,  
4  
5  $p < 0.0001$ ) (Figure 1, Figure 2).

6  
7 During the post-phototherapy phase, TSB  $\pm$ SD ( $153 \pm 51 \mu\text{mol/L}$ ) and TCB  $\pm$ SD ( $143 \pm 63$ )  
8  
9 measurements were statistically significantly different ( $p = 0.0001$ ) (Table 2). These  
10  
11 measurements were taken at median time of 12 hours (IQR 8 - 24) post PT. After cessation of  
12  
13 PT, the correlation between TCB and TSB further improved ( $r = 0.87$ , 95% CI 0.83-0.91,  $p$   
14  
15  $< 0.0001$ ) (Figure 3A). The B-A plot also showed an improvement in the agreement between  
16  
17 TCB and TSB, but TCB continued to underestimate TSB level by  $-10 \pm 31$  (95% agreement  
18  
19 limits of 52 to -72,  $p = 0.0001$ ) (Figure 3B). At 12 hours after cessation of PT, the correlation  
20  
21 between TCB and TSB was improved compared to eight hours post phototherapy with  
22  
23 statistically significantly improving mean difference between TCB and TSB ( $p < 0.0001$ )  
24  
25 (Table 3).

## 36 Discussion

37  
38 Our study revealed a significant correlation between the TCB and TSB during and after  
39  
40 phototherapy in preterm infants. However, our findings also showed a significant wide  
41  
42 disagreement between TCB and TSB measurements during the PT phase. Although TCB  
43  
44 readings from the covered skin had better agreement than those from the exposed skin, TCB  
45  
46 measurements were associated with a large bias during PT. We noted that the TCB device  
47  
48 could underestimate serum bilirubin level by up to 112 and 140  $\mu\text{mol/L}$ , from covered and  
49  
50 uncovered area, respectively, during PT.

51  
52  
53 In general, the significant correlation between TCB and TSB during PT is consistent with the  
54  
55 findings in some previous studies in preterm infants.(20) Cucuy (21) et al conducted a study of  
56  
57 86 preterm infants with a mean gestational age of 32 weeks and a mean birth weight of 1637g.  
58  
59  
60

1  
2  
3 Although they found a good correlation between TSB and TCB during PT ( $r = 0.8$ ), it was not  
4 clear if their TCB readings were measured from the exposed or covered skin during  
5 phototherapy. In addition to this, they did not provide information about the level of agreement  
6 between the TCB and TSB measurements.  
7  
8  
9

10  
11  
12 There are only a few studies that examined 95% agreement limits between the TCB and TSB  
13 in preterm infants during phototherapy. Nagar et al (22) performed a smaller study on 90  
14 preterm infants with a mean gestational age of 32.4 weeks and a mean birth weight of 1847g.  
15 They found that TCB cannot be recommended for the bilirubin measurement during PT in  
16 preterm infants due to the high risk of underestimation of TSB by up to 132 and 157  $\mu\text{mol/L}$   
17 from covered and uncovered skin, respectively. Although their sample was smaller and infants  
18 older than our cohort, their results were quite comparable to our findings.  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 Similarly, Hulzebos et al demonstrated that TCB underestimated TSB in very preterm infants  
29 during phototherapy when measured on covered skin.(18) The same research group proposed  
30 different cut-off rules to improve the prediction of phototherapy thresholds when TCB  
31 measured during phototherapy on covered skin.(18)  
32  
33  
34  
35  
36

37 Zecca et al (23) conducted a study on 364 preterm and term infants requiring phototherapy.  
38 The mean gestational age and the mean birth weight of their sample were of 34.6 weeks of  
39 gestation and 2371g, respectively, which were higher than the mean gestational age and the  
40 mean birth weight of our cohort. They reported a smaller bias between TCB readings from  
41 covered skin and TSB compared to our results. Their results demonstrated that TCB from  
42 exposed skin underestimated TSB by  $54 \pm 51 \mu\text{mol/L}$ , while TCB from covered skin  
43 underestimated TSB by  $3.1 \pm 53 \mu\text{mol/L}$ . However, B-A plots showed a wide TCB-TSB  
44 disagreement with a risk of underestimation of TSB by up to 106  $\mu\text{mol/L}$  from covered skin  
45 and 153  $\mu\text{mol/L}$  from exposed skin.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 We have shown that the TCB readings from both covered and uncovered area were lower than  
4  
5 TSB levels. Immaturity of the skin and the absence of subcutaneous fat in preterm infants  
6  
7 which leads to rapid clearance of extravascular bilirubin levels from the skin following  
8  
9 initiation of PT may be an explanation (9, 24). This however would contravene the findings of  
10  
11 De Luca et al who reported that TCB reading from covered skin and TSB correlated strongly  
12  
13 (r = 0.84, p <0.001) in their study of 60 extremely preterm infants undergoing phototherapy  
14  
15 and, unlike our finding, TCB overestimated TSB with a mean TCB-TSB difference of 47.8  
16  
17  $\pm 41 \mu\text{mol/L}$  (25).  
18  
19

20  
21 During the post-phototherapy phase, our data revealed a better correlation between TCB and  
22  
23 TSB reading as compared to that during the PT phase. More interestingly, the mean difference  
24  
25 of TSB-TCB pairs was much lower than reported previously, even in paired measurements  
26  
27 done in our study as early as eight hours post phototherapy.(18) We observed improved  
28  
29 correlation and decreasing mean difference of TSB-TCB pairs with the increased time post  
30  
31 phototherapy, which would be different to previous observation by Cucuy et al as they reported  
32  
33 that time after PT did not have any significant effect on the correlation between TSB and  
34  
35 TCB.(21)  
36  
37

38  
39 Moreover, our results showed a significant improvement in the agreement between TCB and  
40  
41 TSB after cessation of the PT. The level of underestimation of TSB in our study are similar to  
42  
43 those observed in Nagar et al study (22).  
44  
45

46  
47 The strength of our study is that it is a large prospective observational study that enrolled not  
48  
49 only healthy preterm infants, but also sick and ventilated premature infants. Another notable  
50  
51 strength is that the number of paired TCB-TSB measurements was large in comparison to  
52  
53 previous studies. Finally, we provided recent data for the agreement between TCB and TSB  
54  
55 which is more helpful in clinical practice than correlation coefficient. Thus, our study added  
56  
57  
58  
59  
60

1  
2  
3 significant findings to the limited literature on the use of the TCB device in preterm infants  
4 during and after phototherapy.  
5

6  
7 The present study has some limitations. Firstly, we did not examine the effect of the duration  
8 and recommencement of PT on the TSB-TCB correlation. Also, TCB was only measured from  
9 exposed skin (sternum) after PT was discontinued, and the TCB measurements from the  
10 covered area (nappy area) could have different correlation and agreement with TSB.  
11

12  
13 In conclusion, TCB measurements correlate strongly with TSB levels during and after  
14 phototherapy. However, as a result of the wide and clinically relevant disagreement between  
15 TCB and TSB measurements during the PT phase, a TCB device cannot be recommended for  
16 monitoring bilirubin level during phototherapy in our opinion. However, based on our results,  
17 we would advocate for using TCB for 'rebound' measurements at 12 hours post phototherapy  
18 to avoid unnecessary serum sampling.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

33 **Acknowledgement:** The authors would like to thank all babies and families who  
34 participated in this study along with medical and midwifery staff at the CWIUH.  
35  
36  
37  
38  
39

40 **Contributors:** Dr. Raba designed the study, contributed substantially to the data collection and  
41 analysis and drafted the initial manuscript. Ms. O'Sullivan contributed substantially to the data  
42 collection and analysis and reviewed and revised the manuscript. Prof Miletin conceptualised  
43 and designed the study, supervised the conduct of the study and coordinated the data analysis.  
44 He reviewed and revised the manuscript critically for important intellectual content. All the  
45 authors approved the final manuscript as submitted. They agree to be accountable for all aspects  
46 of the work.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

58 **Compliance with Ethical Statements:**  
59  
60



1  
2  
3 **Conflict of Interest:** The authors declare that they have no conflict of interest  
4

5 **Ethical approval:** The Research Ethics Committee of the Coombe Women and Infants  
6  
7 University Hospital approved the study (Study No.3-2017)  
8  
9

10 **Informed consent:** Informed written consent was obtained from all participants  
11

12 **Funding:** Dr Raba work was supported by the grant from Department of Cultural Affairs,  
13  
14 Libya (Ref: HG6-490-45693) (managed by University College Dublin)  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**What is already known on this topic?**

- Transcutaneous Bilirubinometry (TCB) is a non-invasive test used as a validated screening tool for hyperbilirubinemia in term infants
- The accuracy of TCB measurement during phototherapy (PT) is still controversial in term and preterm infants
- A few studies reported that TCB measurement from covered skin during PT could provide more accurate approximations of Total Serum Bilirubin level in term infants

**What this study adds?**

- During and after PT, TCB measurements correlate significantly with Total Serum Bilirubin (TSB) levels in preterm infants
- During PT, TCB underestimates TSB with a significant wide disagreement between TCB and TSB measurements, making it unreliable despite significant correlation in preterm infants
- Post-phototherapy, there is a significant correlation and acceptable agreement between TCB and TSB measurements with improving performance up to 12 hours after cessation of PT

## References

1. Woodgate P, Jardine LA. Neonatal jaundice. *BMJ Clin Evid*. 2011;15.
2. Watchko JF, Oski FA. Kernicterus in preterm newborns: past, present, and future. *Pediatrics*. 1992;90(5):707-15.
3. Cashore WJ. The neurotoxicity of bilirubin. *Clin Perinatol*. 1990;17(2):437-47.
4. Mitra S, Rennie J. Neonatal jaundice: aetiology, diagnosis and treatment. *Br J Hosp Med (Lond)*. 2017;78(12):699-704.
5. Morris BH, Oh W, Tyson JE, Stevenson DK, Phelps DL, O'Shea TM, et al. Aggressive vs. conservative phototherapy for infants with extremely low birth weight. *N Engl J Med*. 2008;359(18):1885-96.
6. Tyson JE, Pedroza C, Langer J, Green C, Morris B, Stevenson D, et al. Does aggressive phototherapy increase mortality while decreasing profound impairment among the smallest and sickest newborns? *Journal of perinatology : official journal of the California Perinatal Association*. 2012;32(9):677-84. Epub 2012/06/02.
7. Badiee Z, Mohammadzadeh M, Shamee M. Diagnostic usefulness of transcutaneous bilirubinometry in very preterm newborns. *Int J Prev Med*. 2012;3(4):262-5.
8. Ahmed M, Mostafa S, Fisher G, Reynolds TM. Comparison between transcutaneous bilirubinometry and total serum bilirubin measurements in preterm infants <35 weeks gestation. *Ann Clin Biochem*. 2010;47(Pt 1):72-7. Epub 2009/11/25.
9. Ozkan H, Oren H, Duman N, Duman M. Dermal bilirubin kinetics during phototherapy in term neonates. *Acta Paediatr*. 2003;92(5):577-81.
10. Beck M, Kau N, Schlebusch H. Transcutaneous bilirubin measurement in newborn infants: evaluation of a new spectrophotometric method. *Arch Dis Child Fetal Neonatal Ed*. 2003;88(4):F350-1.

11. Nagar G, Vandermeer B, Campbell S, Kumar M. Effect of Phototherapy on the Reliability of Transcutaneous Bilirubin Devices in Term and Near-Term Infants: A Systematic Review and Meta-Analysis. *Neonatology*. 2016;109(3):203-12. Epub 2016/01/21.
12. National Institute for Health and Care Excellence. Jaundice in newborn babies under 28 days  
Clinical guideline [CG98]. 2016.
13. Nagar G, Vandermeer B, Campbell S, Kumar M. Reliability of Transcutaneous Bilirubin Devices in Preterm Infants: A Systematic Review. *Pediatrics*. 2013;132(5):871-81.
14. Hassan Shabuj M, Hossain J, Dey S. Accuracy of transcutaneous bilirubinometry in the preterm infants: a comprehensive meta-analysis. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2019;32(5):734-41.
15. Juster-Reicher A, Flidel-Rimon O, Rozin I, Shinwell ES. Correlation of transcutaneous bilirubinometry (TcB) and total serum bilirubin (TsB) levels after phototherapy. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2015;28(11):1329-31. Epub 2014/09/23.
16. Tan KL, Dong F. Transcutaneous bilirubinometry during and after phototherapy. *Acta Paediatr*. 2003;92(3):327-31.
17. Rylance S, Yan J, Molyneux E. Can transcutaneous bilirubinometry safely guide phototherapy treatment of neonatal jaundice in Malawi? *Paediatr Int Child Health*. 2014;34(2):101-7. Epub 2013/12/06.
18. Hulzebos CV, Vader-van Imhoff DE, Bos AF, Dijk PH. Should transcutaneous bilirubin be measured in preterm infants receiving phototherapy? The relationship between transcutaneous and total serum bilirubin in preterm infants with and without phototherapy. *PloS one*. 2019;14(6):e0218131. Epub 2019/06/15.

- 1  
2  
3 19. Caffrey Oswald E PP. NICE clinical guideline: antibiotics for the prevention and  
4 treatment of early-onset neonatal infection. 2014.  
5  
6  
7  
8 20. Arman D, Topcuoglu S, Gursoy T, Ovali F, Karatekin G. The accuracy of  
9 transcutaneous bilirubinometry in preterm infants. *Journal of perinatology : official journal of*  
10 *the California Perinatal Association.* 2020;40(2):212-8. Epub 2019/08/01.  
11  
12  
13  
14 21. Cucuy M, Juster-Reicher A, Flidel O, Shinwell E. Correlation between transcutaneous  
15 and serum bilirubin in preterm infants before, during, and after phototherapy. *J Matern Fetal*  
16 *Neonatal Med.* 2018;31(10):1323-6. Epub 2017/04/24.  
17  
18  
19  
20 22. Nagar G, Kumar M. Effect of phototherapy on the diagnostic accuracy of  
21 transcutaneous bilirubin in preterm infants. *Journal of Clinical Neonatology.* 2017;6(3):148-  
22 53.  
23  
24  
25  
26 23. Zecca E, Barone G, De Luca D, Marra R, Tiberi E, Romagnoli C. Skin bilirubin  
27 measurement during phototherapy in preterm and term newborn infants. *Early Hum Dev.*  
28 2009;85(8):537-40. Epub 2009/05/29.  
29  
30  
31  
32 24. Kanti V, Bonzel A, Stroux A, Proquitte H, Buhner C, Blume-Peytavi U, et al. Postnatal  
33 maturation of skin barrier function in premature infants. *Skin Pharmacol Physiol.*  
34 2014;27(5):234-41. Epub 2014/07/26.  
35  
36  
37  
38 25. De Luca D, Dell'Orto V. Patched Skin Bilirubin Assay to Monitor Neonates Born  
39 Extremely Preterm Undergoing Phototherapy. *J Pediatr.* 2017;188:122-7. Epub 2017/06/26.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1**  
**Baseline population Characteristics**

Variable	Number
Male Sex n (%)	105 (53.6%)
Birth Weight (grams) Mean $\pm$ SD	1605 $\pm$ 638
Gestational age (weeks) Mean $\pm$ SD	30.4 $\pm$ 3.2
Mode of Delivery n (%)	
NVD	56 (28.6%)
Instrumental Delivery	3 (1.5%)
Elective LSCS	59 (30.1%)
Emergency LSCS	78 (39.8%)
Apgar score at 1 <sup>st</sup> minute Median (IQR)	7 (5-9)
Apgar score at 5 <sup>th</sup> minute Median (IQR)	9 (8-10)
Blood group infants (when done) n (%)	175 (89%)
A	48 (27.4%)
B	18 (10.2%)
AB	2 (1%)
O	108 (61.7%)
Rhesus +	150/175 (85.7%)
Maternal group n (%)	
A	60 (30.6%)
B	24 (12.2%)
AB	5 (2.6%)
O	104 (53.1%)
Rhesus +	176 (89.9%)
Positive DCT n (%)	7 (3.6%)
Maternal age (years) Mean $\pm$ SD	32 $\pm$ 6.2
Proven EOS n (%)	5 (2%)
Antibiotics treatment n (%)	145 (74%)

NVD, normal vaginal delivery; DCT, direct Coombs test; LSCS, lower segment Caesarean section; EOS, early onset sepsis

**Table 2**  
**Paired samples of TSB and TCB from covered and uncovered skin during phototherapy and post phototherapy**

		Mean $\pm$ SD $\mu\text{mol/l}$	Median (IQR) $\mu\text{mol/l}$	N	P-value
During PT	TCBC	102 $\pm$ 62	102 (55, 146)	299	<0.0001
	TSB	127 $\pm$ 51	124 (89, 162)		
	TCBC - TSB difference	-25 $\pm$ 43	-25 (-49, 1)		
During PT	TCBU	79 $\pm$ 70	61 (18, 127)	309	<0.0001
	TSB	127 $\pm$ 51	122 (86, 162)		
	TCBU - TSB difference	-48 $\pm$ 46	-48 (-79, -18)		
After PT	TCB	143 $\pm$ 63	141 (100, 188)	142	0.0001
	TSB	153 $\pm$ 51	153 (115, 187)		
	TCBC - TSB difference	-10 $\pm$ 31	-13 (-28, 9)		

TSB, total serum bilirubin; TCBC, Transcutaneous bilirubinometry readings from covered skin; TCBU, Transcutaneous bilirubinometry readings from exposed skin; PT, phototherapy; TCB, Transcutaneous bilirubinometry

**Table 3**  
**TCB and TSB pairs 8 and 12 hour post phototherapy**

Hours after PT	N	TSB ( $\mu\text{mol/l}$ ) Mean $\pm$ SD Median (IQR)	TCB ( $\mu\text{mol/l}$ ) Mean $\pm$ SD Median (IQR)	Mean difference (TCB – TSB) ( $\mu\text{mol/l}$ ) Mean $\pm$ SD Median (IQR)	Correlation r (p value)
8 hours	40	133 $\pm$ 51 124 (94, 168)	95 $\pm$ 54 97 (53, 138)	-37 $\pm$ 28 -32 (-49, -22)	0.86 (< 0.0001)
12 hours	36	147 $\pm$ 52 135 (112, 173)	131 $\pm$ 51 123 (95, 154)	-16 $\pm$ 19 -17 (-23, -7)	0.93 (< 0.0001)

TSB, total serum bilirubin; TCB, Transcutaneous bilirubinometry; PT, phototherapy



## Legends

### Figure 1A

Correlation between Total Serum Bilirubin (TSB) and Transcutaneous Bilirubinometry (TCB) from covered skin during phototherapy

### Figure 1B

B–A plot showing the 95% limits of agreement between TCB from covered skin and TSB during phototherapy

### Figure 2A

Correlation between Total Serum Bilirubin (TSB) and Transcutaneous Bilirubinometry (TCB) from uncovered skin during phototherapy

### Figure 2B

B–A plot showing the 95% limits of agreement between TCB from uncovered skin and TSB during phototherapy

### Figure 3A

Correlation between Total Serum Bilirubin (TSB) and Transcutaneous Bilirubinometry (TCB) after phototherapy

### Figure 3B

B–A plot showing the 95% limits of agreement between TCB and TSB after phototherapy

## Appendix 1


1  
2  
3 National Institute for Health and Care Excellence Guideline charts for phototherapy, used for  
4  
5 infants less than 32 weeks of gestation  
6  
7  
8  
9

10 Appendix 2

11  
12 Phototherapy threshold chart used for infants  $\geq 32$  weeks of gestation (adapted from National  
13  
14 Health Service, Glasgow, UK)  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


Confidential: For Review Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




296x209mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



296x209mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



296x209mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Neonatal jaundice

## Treatment threshold graphs

Graphs for assessing whether to treat neonatal jaundice by phototherapy or exchange transfusion

2010

**NICE clinical guideline 98**





*National Institute for  
Health and Clinical Excellence*

The NCC-WCH and the Guideline Development Group (GDG) would like to thank Dr Giles Kendall MBBS, BSc(hons), MRCPCH PhD Academic Clinical Lecturer Neonatal Medicine University College London / University College London Hospital NHS Foundation Trust, T J Cole, Professor of Medical Statistics, MRC Centre of Epidemiology for Child Health, UCL Institute of Child Health and Janet Rennie, Consultant and Senior Lecturer in Neonatal Medicine, Elizabeth Garrett Anderson Institute for Women's Health, University College London NHS Foundation Trust London for allowing the GDG to adapt their excel spreadsheet in developing the treatment threshold graphs included in this guideline.



*National Institute for  
Health and Clinical Excellence*

## Treatment threshold graphs for neonatal jaundice - Instructions

These treatment threshold graphs will help healthcare professionals assess whether babies with jaundice should be given phototherapy or exchange transfusion. Please access the graphs directly from the NICE website to ensure that you are using the correct version of them.

**Click on the 'Treatment threshold graphs' tab to access the graphs. The sheet contains a treatment graph for each gestational age. Before printing, use the drop-down menu that is marked in red to choose the graph for the correct gestational age for each baby with jaundice.**

Print off the graph and keep it with the baby's notes. Plot the baby's bilirubin level on the graph each time it is measured, against the baby's age. Each line on the horizontal (x) axis is equal to 6 hours and each line on the vertical (y) axis is equal to 10 micromol/ litre. Assess whether the threshold for either phototherapy or exchange transfusion has been reached. Refer to the NICE neonatal jaundice guideline for detailed recommendations about the treatment of neonatal jaundice [www.nice.org.uk/guidance/CG98/QuickRefGuide](http://www.nice.org.uk/guidance/CG98/QuickRefGuide). Shade the 'single' or 'multiple' cells to show the type of phototherapy that the baby is receiving on each day.

**Following a query to NICE about how the treatment threshold graphs for babies with jaundice should be used, please note:** The graph that reflects the baby's actual gestational age should continue to be used until the baby is 14 days old. The baby's 'corrected' gestational age should not be taken into consideration, and you should not move up to the next graph when the baby is 7 days old. For example, for a baby of 35 weeks' gestation, the 35-week gestation graph should be used until the baby is aged 14 days. Please note that the NICE guideline does not cover treatment with phototherapy and exchange transfusion for babies older than 14 days. Trusts should therefore agree their own policy about when to treat babies over 14 days with phototherapy and exchange transfusion.

The NICE neonatal jaundice guideline and all implementation tools can be found at [www.nice.org.uk/guidance/CG98](http://www.nice.org.uk/guidance/CG98)




# Treatment threshold graph for babies with neonatal jaundice



1 Baby's name \_\_\_\_\_ Date of birth \_\_\_\_\_  
 2  
 3  
 4 Hospital number \_\_\_\_\_ Time of birth \_\_\_\_\_ Direct Antiglobulin Test \_\_\_\_\_  
 5  
 6  
 7  
 8 Shade for phototherapy \_\_\_\_\_ Baby's blood group \_\_\_\_\_ Mother's blood group \_\_\_\_\_  
 9

Click below and choose gestation

**26** weeks gestation



41  
42  
43  
44  
45  
46

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Confidential: For Review Only



**National Institute for  
Health and Clinical Excellence**

## Where to find the guidance

The NICE neonatal jaundice guideline contains recommendations about the recognition, assessment and treatment of neonatal jaundice.

You can download the following documents from [www.nice.org.uk/guidance/CG98](http://www.nice.org.uk/guidance/CG98).

- The NICE guideline – all the recommendations
- The full guideline – all the recommendations, details of how they were developed and summaries of the evidence they were based on
- The quick reference guide – a summary of the recommendations for healthcare professionals ([www.nice.org.uk/guidance/CG98/QuickRefGuide](http://www.nice.org.uk/guidance/CG98/QuickRefGuide))
- ‘Understanding NICE guidance’ – a version of the guideline for parents and carers

For printed copies of the quick reference guide or ‘Understanding NICE guidance’ phone NICE publications on 0845 003 7783 or email [publications@nice.org.uk](mailto:publications@nice.org.uk) and quote:


- N2143 – (quick reference guide)
- N2144 – (‘Understanding NICE guidance’)

Other implementation tools are available from the NICE website:

- slide set
- parent information factsheet
- audit tools
- costing tools

National Institute for Health and Clinical Excellence  
71 High Holborn  
London  
WC1V 6NA  
[www.nice.org.uk](http://www.nice.org.uk)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



338x190mm (300 x 300 DPI)

# BMJ Paediatrics Open

## Transcutaneous Bilirubinometry during and after Phototherapy in Preterm Infants, Prospective Observational Study

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2020-000681.R2
Article Type:	Original research
Date Submitted by the Author:	03-Jun-2020
Complete List of Authors:	Raba, Ali ; Coombe Women and Infants University Hospital O'Sullivan, Anne; Coombe Women and Infants University Hospital, Miletin, Jan; Coombe Women and Infants University Hospital, Paediatric and Newborn Medicine
Keywords:	Jaundice, Neonatology, Monitoring

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 **Transcutaneous Bilirubinometry during and after Phototherapy in Preterm Infants,**  
4  
5 **Prospective Observational Study**  
6

7 Ali Ahmed Raba<sup>1,2</sup>, Anne O'Sullivan<sup>2</sup>, Jan Miletin<sup>1,2,3,4</sup>  
8  
9

10 <sup>1</sup> UCD School of Medicine and Medical Sciences, Dublin, Ireland  
11

12 <sup>2</sup> Coombe Women and Infants University Hospital, Dublin, Ireland  
13

14 <sup>3</sup> Institute for the Care of Mother and Child, Prague, Czech Republic  
15

16 <sup>4</sup> 3rd School of Medicine, Charles University, Prague, Czech Republic  
17  
18  
19

20 **Short running title:** Transcutaneous Bilirubinometry in Preterm Infants  
21

22 **Corresponding author:** Prof Jan Miletin, MD, FRCPI, FJFICMI  
23

24 **Address:** Coombe Women and Infants University Hospital, Cork Street, Dublin 8, Dublin,  
25  
26  
27 Ireland  
28

29 **Email:** miletinj@yahoo.com  
30

31 **Telephone:** 00353 14085654  
32

33 **Fax:** 00353 14085209  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Objective:** To examine the accuracy of Transcutaneous Bilirubinometry (TCB) measurements during and after phototherapy (PT) in preterm infants

**Design:** Prospective observational cohort study

**Setting:** Level III neonatal centre.

**Patients:** Preterm infants ( $23^{+0}$  to  $36^{+6}$  weeks of gestation) born between June 2017 and May 2018 requiring PT

**Interventions:** TCB was measured from an exposed area of skin (the sternum, (TCBU)) and covered area of skin under the nappy (the bony part of the upper outer quadrant of the buttock (TCBC)) within an hour of obtaining Total Serum Bilirubin (TSB)

**Main outcome measures:** Correlation and agreement between TCB (TCBU and TCBC) and TSB during and after phototherapy

**Result:** We have enrolled 196 preterm infants. There was a significant correlation between TSB and TCB during PT ( $r = 0.72$ , 95% CI 0.66 to 0.77 in covered,  $r = 0.75$ , 95% CI 0.70 to 0.80 in uncovered areas) and after PT ( $r = 0.87$ , 95% CI 0.83 to 0.91). TCB underestimated TSB level during PT with a mean TCBC-TSB difference of  $-25 \pm 43$ , 95% agreement limits of 62 to -112, and a mean TCBU-TSB difference of  $-48 \pm 46$ , 95% agreement limits of 45 to -140. The agreement between TCB and TSB after cessation of PT improved, TCB underestimating TSB by a mean TCB-TSB difference of  $-10 \pm 31$  (95% agreement limits of 52 to -72).

**Conclusion:** TCB measurements correlated strongly with TSB levels during and after phototherapy. However, there was a wide and clinically relevant disagreement between TCB and TSB measurements during PT phase, improving significantly post PT.

**Keywords:** Hyperbilirubinemia, Jaundice, Preterm infants, Transcutaneous bilirubinometry



1  
2  
3 **Abbreviations:** B-A, Bland-Altman; CWIUH, Coombe Women and Infants University  
4 hospital; DCT, direct Coombs test; GIT, gastrointestinal tract; IQR, interquartile range; mVSD,  
5 muscular ventricular septal defect; NICE, National Institute for Health and Care Excellence;  
6 PDA, patent ductus arteriosus; PFO, persistent foramen ovale; PT, phototherapy; SD, standard  
7 deviation; TCB, transcutaneous bilirubinometry; TCBC, transcutaneous bilirubinometry  
8 reading from covered skin; TCBU, transcutaneous bilirubinometry reading from uncovered  
9 skin; TSB, total serum bilirubin  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Neonatal hyperbilirubinemia is a very common condition with approximately 50% of term and 80% of preterm infants developing jaundice in the first week of life <sup>1</sup>. Hyperbilirubinemia in most cases is a benign and self-limiting condition, however severe hyperbilirubinemia can occasionally occur and may be associated with irreversible brain damage, especially in preterm infants <sup>2,3</sup>.

Phototherapy (PT) is considered to be a safe and effective treatment for neonatal unconjugated hyperbilirubinemia. The indication to commence treatment is based on the level of serum bilirubin, the age of the baby in hours, and gestational age <sup>4</sup>. Evidence is conflicting regarding the best therapeutic approach to hyperbilirubinemia, especially in extremely low birth weight (ELBW) infants. A randomised clinical trial (RCT) performed by the Neonatal Research Network found no significant difference in the rate of death or neurodevelopmental impairment at 18 to 22 months corrected age in ELBW infants who received aggressive PT versus those who received conservative PT. However, aggressive PT was associated with a reduction in the rate of neurodevelopmental impairment alone.<sup>5</sup> However, the post hoc analysis showed that in the smallest and sickest subgroup (mechanically ventilated infants with birth weight less than 750g), aggressive PT may increase mortality while reducing neurodevelopmental impairment.<sup>6</sup>

Measurement of total serum bilirubin (TSB) remains the gold standard for monitoring bilirubin levels during and after PT in term and preterm infants. However, obtaining heel stick or venous blood samples is painful, time-consuming, and increases the risk of local and systemic infection especially in preterm infants <sup>7</sup>. A transcutaneous bilirubinometry (TCB) device works by directing light into the skin of the infant and measuring and analysing the intensity of the returned wavelengths to estimate a TSB <sup>8</sup>. TCB has been recommended as a non-invasive, painless and time-saving test for bilirubin estimation in term and late preterm infants prior to the commencement of PT <sup>9-11</sup>. However, TCB measurements are not recommended in the first

1  
2  
3 24 hours of life or in preterm infants below 35 weeks of gestation according to the National  
4  
5 Institute for Clinical Excellence (NICE) guidelines.<sup>12</sup>  
6  
7 (<https://www.nice.org.uk/guidance/cg98>).  
8  
9

10 It seems that TCB has strong correlation and acceptable agreement in preterm infants before  
11  
12 phototherapy.<sup>13 14</sup> The use of TCB for infants during and after PT is still controversial, as some  
13  
14 studies reported that PT blanches the skin thereby affecting the correlation between TCB and  
15  
16 TSB during and after phototherapy<sup>15</sup> while others suggest that TCB readings from covered skin  
17  
18 area could be safely used to guide treatment during and post PT.<sup>16-18</sup> We designed our study  
19  
20 to examine the accuracy of TCB to estimate the TSB level in preterm infants undergoing PT  
21  
22 and its reliability after PT.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Methods

A single centre prospective observational cohort study performed in the neonatal department of the Coombe Women and Infants University hospital (CWIUH), Dublin, Ireland (level III neonatal centre). All preterm infants (23+0 - 36+6 weeks of gestation) born between June 2017 and May 2018 in CWIUH who developed significant jaundice requiring PT were eligible for enrollment to this study. During the study period, the protocols for screening, diagnosis and management of infants with jaundice were not changed. Infants with clinical or radiological evidence of major congenital anomalies (including those with gastrointestinal tract (GIT) deformities and congenital heart diseases apart from patent ductus arteriosus (PDA), persistent foramen ovale (PFO) and small ( $\leq 5$  mm) muscular ventricular septal defect (mVSD)) were excluded from this study.

PT was commenced based on TSB levels according to the hospital guidelines, taking into account the infant's age in hours and gestation in weeks. The NICE treatment charts were used for preterm infants below 32 weeks of gestation (<https://www.nice.org.uk/guidance/cg98/resources>). In infants  $\geq 32$  weeks of gestation, a chart adapted from the National Health Service (NHS), Glasgow, UK was used (Appendix 1). Standard PT units (Photo Therapy 4000, Draeger Medical, Germany) were used (overhead PT microlight units deliver  $\geq 10$   $\mu\text{W}/\text{cm}^2/\text{nm}$  and Halogen spotlights which can deliver 20-25  $\mu\text{W}/\text{cm}^2/\text{nm}$ ). Infants receiving PT were completely exposed, except for their eyes (covered with phototherapy goggles for protection) and the nappy area (covered with a disposable nappy). PT was discontinued when the TSB fell below the relevant treatment threshold.

TCB was measured from uncovered/exposed (TCBU) and covered (TCBC) areas within an hour of obtaining TSB samples. The device was placed over an uncovered area (sternum) and pressed gently against the skin three times to obtain one reading (the average of the three measured values). The process was repeated over the covered area, the bony part of the upper

1  
2  
3 outer quadrant of the buttock (covered by the nappy). After cessation of PT, TCB's were  
4  
5 measured from the sternum. The measurements were obtained by experienced nurses trained  
6  
7 and competent in the use of the Dräger Jaundice Meter (JM-105 or JM-103, Draeger Medical,  
8  
9 Germany). The TCB devices were calibrated regularly according to the manufacturer's  
10  
11 instructions and hospital guidelines. Blood samples for TSB were obtained either by heel prick  
12  
13 or venepuncture. The attending neonatologist directed the frequency of TSB measurements.  
14  
15 TSB levels were measured in one clinical laboratory using direct spectrophotometry (Abbot  
16  
17 Architect C8000, Abbott, USA).

18  
19  
20  
21 Our primary outcome was the correlation and agreement between TCB (TCBU and TCBC)  
22  
23 and TSB during and after PT.

24  
25  
26 Our prospective cohort study was approved by the Research Ethics Committee of the CWIUH  
27  
28 (Study No.3-2017) and informed written consent was obtained from parents. Patients or the  
29  
30 public were not involved in the design, conduct, or reporting plans of our research.

31  
32  
33 Data was entered into Microsoft Office Excel (MS Excel, Microsoft, USA) and analysed by  
34  
35 the StatsDirect v.3.2.10 software (StatsDirect Ltd, UK). Descriptive statistics were used for all  
36  
37 demographic variables of interest using frequency distribution and percentage for categorical  
38  
39 variables. Mean and standard deviation (SD) were used for normally distributed data, while  
40  
41 non normal distribution data was summarised using median and interquartile range (IQR).  
42  
43 Paired-samples t-test was used to compare TCB and TSB paired measurements. When the  
44  
45 differences between pairs were not normally distributed, we used the Wilcoxon signed-rank  
46  
47 test for two sample comparisons. For independent variables we have used an unpaired t-test or  
48  
49 Mann-Whitney U test as appropriate. Correlation between TCB (TCBU and TCBC) and TSB  
50  
51 was calculated using Pearson's correlation coefficient during and after phototherapy. Bland-  
52  
53 Altman (B-A) analysis was used to calculate and visualize the agreement between TSB and  
54  
55 TCB. The agreement limits are demonstrated as a 95% confidence interval (95% CI = mean  $\pm$   
56  
57  
58  
59  
60

1.96 standard deviations), where the ideal agreement difference between measurements is zero. Our results were summarized using p-values and 95% confidence intervals. P-values <0.05 were considered to be statistically significant. We have used a convenience sample for the study with planned one year enrolment.

## Results

One hundred and ninety six jaundiced preterm infants who received phototherapy were enrolled to the study. The mean ( $\pm$ SD) gestational age and birth weight of our cohort were 30.4 weeks of gestation ( $\pm$ 3.2) and 1605g ( $\pm$ 638), respectively. The demographic description of our cohort is presented in the Table 1.

There were 328 simultaneous measurements (TSB and TCB) during the PT phase and 142 pairs of readings after discontinuation of PT. The PT was commenced at mean ( $\pm$ SD) 32.5 ( $\pm$ 20) hours of life and the median duration of PT exposure was 24 hours (IQR 24-32).

During the PT phase, the mean TSB  $\pm$ SD (127  $\pm$ 51  $\mu$ mol/L) and mean TCBC  $\pm$ SD (102  $\pm$ 62) were statistically significantly different ( $p < 0.0001$ ) (Table 2). Similarly, the difference between the mean TSB  $\pm$ SD (127  $\pm$ 51  $\mu$ mol/L) and mean TCBU  $\pm$ SD (79  $\pm$ 70) was statistically significantly different during PT ( $p < 0.0001$ ) (Table 2). Although there was a significant correlation between TSB and TCB measurements during PT, ( $r = 0.72$ , 95% CI 0.66 to 0.77 from covered,  $r = 0.75$ , 95% CI 0.70 to 0.80 from uncovered areas,  $p < 0.0001$ ), B-A plots showed significant bias and imprecisions in the TCB readings. TCB underestimated TSB level with a mean TCB-TSB difference of -25  $\pm$ 43 from covered area (95% agreement limits of 62 to -112,  $p < 0.0001$ ) and of -48  $\pm$ 46 from uncovered area (95% agreement limits of 45 to -140,  $p < 0.0001$ ) (Figure 1, Figure 2).

During the post-phototherapy phase, TSB  $\pm$ SD (153  $\pm$ 51  $\mu$ mol/L) and TCB  $\pm$ SD (143  $\pm$ 63) measurements were statistically significantly different ( $p = 0.0001$ ) (Table 2). These

1  
2  
3 measurements were taken at median time of 12 hours (IQR 8 - 24) post PT. After cessation of  
4  
5 PT, the correlation between TCB and TSB further improved ( $r = 0.87$ , 95% CI 0.83-0.91,  $p$   
6  
7  $< 0.0001$ ) (Figure 3A). The B-A plot also showed an improvement in the agreement between  
8  
9 TCB and TSB, but TCB continued to underestimate TSB level by  $-10 \pm 31$  (95% agreement  
10  
11 limits of 52 to -72,  $p = 0.0001$ ) (Figure 3B). At 12 hours after cessation of PT, the correlation  
12  
13 between TCB and TSB was improved compared to eight hours post phototherapy with  
14  
15 statistically significantly improving mean difference between TCB and TSB ( $p < 0.0001$ )  
16  
17 (Table 3).  
18  
19  
20  
21  
22  
23  
24  
25

## 26 Discussion

27  
28 Our study revealed a significant correlation between the TCB and TSB during and after  
29  
30 phototherapy in preterm infants. However, our findings also showed a significant wide  
31  
32 disagreement between TCB and TSB measurements during the PT phase. Although TCB  
33  
34 readings from the covered skin had better agreement than those from the exposed skin, TCB  
35  
36 measurements were associated with a large bias during PT. We noted that the TCB device  
37  
38 could underestimate serum bilirubin level by up to 112 and 140  $\mu\text{mol/L}$ , from covered and  
39  
40 uncovered area, respectively, during PT.  
41  
42  
43

44  
45 In general, the significant correlation between TCB and TSB during PT is consistent with the  
46  
47 findings in some previous studies in preterm infants.<sup>19</sup> Cucuy<sup>20</sup> et al conducted a study of 86  
48  
49 preterm infants with a mean gestational age of 32 weeks and a mean birth weight of 1637g.  
50  
51 Although they found a good correlation between TSB and TCB during PT ( $r = 0.8$ ), it was not  
52  
53 clear if their TCB readings were measured from the exposed or covered skin during  
54  
55 phototherapy. In addition to this, they did not provide information about the level of agreement  
56  
57 between the TCB and TSB measurements.  
58  
59  
60

1  
2  
3 There are only a few studies that examined 95% agreement limits between the TCB and TSB  
4  
5 in preterm infants during phototherapy. Nagar et al <sup>21</sup> performed a smaller study on 90 preterm  
6  
7 infants with a mean gestational age of 32.4 weeks and a mean birth weight of 1847g. They  
8  
9 found that TCB cannot be recommended for the bilirubin measurement during PT in preterm  
10  
11 infants due to the high risk of underestimation of TSB by up to 132 and 157  $\mu\text{mol/L}$  from  
12  
13 covered and uncovered skin, respectively. Although their sample was smaller and infants older  
14  
15 than our cohort, their results were quite comparable to our findings.  
16  
17

18  
19 Similarly, Hulzebos et al demonstrated that TCB underestimated TSB in very preterm infants  
20  
21 during phototherapy when measured on covered skin.<sup>18</sup> The same research group proposed  
22  
23 different cut-off rules to improve the prediction of phototherapy thresholds when TCB  
24  
25 measured during phototherapy on covered skin.<sup>18</sup>  
26  
27

28  
29 Zecca et al <sup>22</sup> conducted a study on 364 preterm and term infants requiring phototherapy. The  
30  
31 mean gestational age and the mean birth weight of their sample were of 34.6 weeks of gestation  
32  
33 and 2371g, respectively, which were higher than the mean gestational age and the mean birth  
34  
35 weight of our cohort. They reported a smaller bias between TCB readings from covered skin  
36  
37 and TSB compared to our results. Their results demonstrated that TCB from exposed skin  
38  
39 underestimated TSB by  $54 \pm 51 \mu\text{mol/L}$ , while TCB from covered skin underestimated TSB by  
40  
41  $3.1 \pm 53 \mu\text{mol/L}$ . However, B-A plots showed a wide TCB-TSB disagreement with a risk of  
42  
43 underestimation of TSB by up to  $106 \mu\text{mol/L}$  from covered skin and  $153 \mu\text{mol/L}$  from exposed  
44  
45 skin.  
46  
47

48  
49 We have shown that the TCB readings from both covered and uncovered area were lower than  
50  
51 TSB levels. We speculate, that immaturity of the skin and the absence of subcutaneous fat in  
52  
53 preterm infants may lead to rapid clearance of extravascular bilirubin levels from the skin  
54  
55 following initiation of PT <sup>9 23</sup>. This however would contravene the findings of De Luca et al  
56  
57 who reported that TCB reading from covered skin and TSB correlated strongly ( $r = 0.84$ ,  $p$   
58  
59  
60



1  
2  
3 <0.001) in their study of 60 extremely preterm infants undergoing phototherapy and, unlike  
4 our finding, TCB overestimated TSB with a mean TCB-TSB difference of  $47.8 \pm 41 \mu\text{mol/L}$  <sup>24</sup>.  
5  
6  
7  
8 During the post-phototherapy phase, our data revealed a better correlation between TCB and  
9  
10 TSB reading as compared to that during the PT phase. More interestingly, the mean difference  
11  
12 of TSB-TCB pairs was much lower than reported previously, even in paired measurements  
13  
14 done in our study as early as eight hours post phototherapy.<sup>18</sup> We observed improved  
15  
16 correlation and decreasing mean difference of TSB-TCB pairs with the increased time post  
17  
18 phototherapy, which would be different to previous observation by Cucuy et al as they reported  
19  
20 that time after PT did not have any significant effect on the correlation between TSB and  
21  
22 TCB.<sup>20</sup>  
23  
24

25  
26 Moreover, our results showed a significant improvement in the agreement between TCB and  
27  
28 TSB after cessation of the PT. The level of underestimation of TSB in our study are similar to  
29  
30 those observed in Nagar et al study <sup>21</sup>.  
31  
32

33  
34 The strength of our study is that it is a large prospective observational study with substantial  
35  
36 number of paired TCB-TSB measurements in comparison to previous studies. We have also  
37  
38 provided recent data for the agreement between TCB and TSB which is more helpful in clinical  
39  
40 practice than correlation coefficient. Thus, our study added significant findings to the literature  
41  
42 on the use of the TCB device in preterm infants during and after phototherapy.  
43  
44

45  
46 The present study has some limitations. Firstly, we did not examine the effect of the duration  
47  
48 and recommencement of PT on the TSB-TCB correlation. Also, TCB was only measured from  
49  
50 exposed skin (sternum) after PT was discontinued, and the TCB measurements from the  
51  
52 covered area (nappy area) could have different correlation and agreement with TSB.  
53

54  
55 In conclusion, TCB measurements correlate strongly with TSB levels during and after  
56  
57 phototherapy. However, as a result of the wide and clinically relevant disagreement between  
58  
59 TCB and TSB measurements during the PT phase, a TCB device cannot be recommended for  
60

1  
2  
3 monitoring bilirubin level during phototherapy in our opinion. However, based on our results,  
4 we would advocate for using TCB for TSB 'rebound' measurements at 12 hours post  
5 phototherapy to avoid unnecessary serum sampling.  
6  
7  
8  
9

10  
11  
12 **Acknowledgement:** The authors would like to thank all babies and families who  
13 participated in this study along with medical and midwifery staff at the CWIUH.  
14  
15  
16

17  
18  
19 **Contributors:** Dr. Raba designed the study, contributed substantially to the data collection and  
20 analysis and drafted the initial manuscript. Ms. O'Sullivan contributed substantially to the data  
21 collection and analysis and reviewed and revised the manuscript. Prof Miletin conceptualised  
22 and designed the study, supervised the conduct of the study and coordinated the data analysis.  
23 He reviewed and revised the manuscript critically for important intellectual content. All the  
24 authors approved the final manuscript as submitted. They agree to be accountable for all aspects  
25 of the work.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 **Compliance with Ethical Statements:**

39  
40 **Conflict of Interest:** The authors declare that they have no conflict of interest  
41

42 **Ethical approval:** The Research Ethics Committee of the Coombe Women and Infants  
43 University Hospital approved the study (Study No.3-2017)  
44  
45

46 **Informed consent:** Informed written consent was obtained from all participants  
47

48  
49 **Funding:** Dr Raba work was supported by the grant from Department of Cultural Affairs,  
50 Libya (Ref: HG6-490-45693) (managed by University College Dublin)  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### What is already known on this topic?

- Transcutaneous Bilirubinometry (TCB) is a non-invasive test used as a validated screening tool for hyperbilirubinemia in term infants
- The accuracy of TCB measurement during phototherapy (PT) is still controversial in term and preterm infants
- A few studies reported that TCB measurement from covered skin during PT could provide accurate approximations of Total Serum Bilirubin level in term infants

### What this study adds?

- During and after PT, TCB measurements correlate significantly with Total Serum Bilirubin (TSB) levels in preterm infants
- During PT, TCB underestimates TSB with a significant wide disagreement between TCB and TSB measurements, making it unreliable
- Post-phototherapy, there is a significant correlation and acceptable agreement between TCB and TSB measurements with improving performance up to 12 hours after cessation of PT

## References

1. Woodgate P, Jardine LA. Neonatal jaundice. *BMJ Clin Evid* 2011;15
2. Watchko JF, Oski FA. Kernicterus in preterm newborns: past, present, and future. *Pediatrics* 1992;90(5):707-15.
3. Cashore WJ. The neurotoxicity of bilirubin. *Clin Perinatol* 1990;17(2):437-47.
4. Mitra S, Rennie J. Neonatal jaundice: aetiology, diagnosis and treatment. *Br J Hosp Med (Lond)* 2017;78(12):699-704. doi: 10.12968/hmed.2017.78.12.699
5. Morris BH, Oh W, Tyson JE, et al. Aggressive vs. conservative phototherapy for infants with extremely low birth weight. *N Engl J Med* 2008;359(18):1885-96. doi: 10.1056/NEJMoa0803024
6. Tyson JE, Pedroza C, Langer J, et al. Does aggressive phototherapy increase mortality while decreasing profound impairment among the smallest and sickest newborns? *Journal of perinatology : official journal of the California Perinatal Association* 2012;32(9):677-84. doi: 10.1038/jp.2012.64 [published Online First: 2012/06/02]
7. Badiie Z, Mohammadizadeh M, Shamee M. Diagnostic usefulness of transcutaneous bilirubinometry in very preterm newborns. *Int J Prev Med* 2012;3(4):262-5.
8. Ahmed M, Mostafa S, Fisher G, et al. Comparison between transcutaneous bilirubinometry and total serum bilirubin measurements in preterm infants <35 weeks gestation. *Ann Clin Biochem* 2010;47(Pt 1):72-7. doi: 10.1258/acb.2009.009072 [published Online First: 2009/11/25]
9. Ozkan H, Oren H, Duman N, et al. Dermal bilirubin kinetics during phototherapy in term neonates. *Acta Paediatr* 2003;92(5):577-81.
10. Beck M, Kau N, Schlebusch H. Transcutaneous bilirubin measurement in newborn infants: evaluation of a new spectrophotometric method. *Arch Dis Child Fetal Neonatal Ed* 2003;88(4):F350-1.

- 1  
2  
3 11. Nagar G, Vandermeer B, Campbell S, et al. Effect of Phototherapy on the Reliability of  
4  
5 Transcutaneous Bilirubin Devices in Term and Near-Term Infants: A Systematic  
6  
7 Review and Meta-Analysis. *Neonatology* 2016;109(3):203-12. doi:  
8  
9 10.1159/000442195 [published Online First: 2016/01/21]  
10  
11
- 12 12. National Institute for Health and Care Excellence. Jaundice in newborn babies under 28  
13  
14 days Clinical guideline [CG98], 2016.  
15  
16
- 17 13. Nagar G, Vandermeer B, Campbell S, et al. Reliability of Transcutaneous Bilirubin Devices  
18  
19 in Preterm Infants: A Systematic Review. *Pediatrics* 2013;132(5):871-81. doi:  
20  
21 10.1542/peds.2013-1713  
22  
23
- 24 14. Hassan Shabuj M, Hossain J, Dey S. Accuracy of transcutaneous bilirubinometry in the  
25  
26 preterm infants: a comprehensive meta-analysis. *The Journal of Maternal-Fetal &*  
27  
28 *Neonatal Medicine* 2019;32(5):734-41. doi: 10.1080/14767058.2017.1390561  
29  
30
- 31 15. Juster-Reicher A, Flidel-Rimon O, Rozin I, et al. Correlation of transcutaneous  
32  
33 bilirubinometry (TcB) and total serum bilirubin (TsB) levels after phototherapy. *The*  
34  
35 *journal of maternal-fetal & neonatal medicine : the official journal of the European*  
36  
37 *Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal*  
38  
39 *Societies, the International Society of Perinatal Obstet* 2015;28(11):1329-31. doi:  
40  
41 10.3109/14767058.2014.953923 [published Online First: 2014/09/23]  
42  
43  
44
- 45 16. Tan KL, Dong F. Transcutaneous bilirubinometry during and after phototherapy. *Acta*  
46  
47 *Paediatr* 2003;92(3):327-31.  
48
- 49 17. Rylance S, Yan J, Molyneux E. Can transcutaneous bilirubinometry safely guide  
50  
51 phototherapy treatment of neonatal jaundice in Malawi? *Paediatr Int Child Health*  
52  
53 2014;34(2):101-7. doi: 10.1179/2046905513Y.0000000050 [published Online First:  
54  
55 2013/12/06]  
56  
57  
58  
59  
60

- 1  
2  
3 18. Hulzebos CV, Vader-van Imhoff DE, Bos AF, et al. Should transcutaneous bilirubin be  
4 measured in preterm infants receiving phototherapy? The relationship between  
5 transcutaneous and total serum bilirubin in preterm infants with and without  
6 phototherapy. *PloS one* 2019;14(6):e0218131. doi: 10.1371/journal.pone.0218131  
7 [published Online First: 2019/06/15]  
8  
9  
10  
11  
12  
13  
14  
15 19. Arman D, Topcuoglu S, Gursoy T, et al. The accuracy of transcutaneous bilirubinometry  
16 in preterm infants. *Journal of perinatology : official journal of the California Perinatal*  
17 *Association* 2020;40(2):212-18. doi: 10.1038/s41372-019-0445-3 [published Online  
18 First: 2019/08/01]  
19  
20  
21  
22  
23  
24 20. Cucuy M, Juster-Reicher A, Flidel O, et al. Correlation between transcutaneous and serum  
25 bilirubin in preterm infants before, during, and after phototherapy. *J Matern Fetal*  
26 *Neonatal Med* 2018;31(10):1323-26. doi: 10.1080/14767058.2017.1315662 [published  
27 Online First: 2017/04/24]  
28  
29  
30  
31  
32  
33 21. Nagar G, Kumar M. Effect of phototherapy on the diagnostic accuracy of transcutaneous  
34 bilirubin in preterm infants. *Journal of Clinical Neonatology* 2017;6(3):148-53. doi:  
35 10.4103/jcn.JCN\_94\_16  
36  
37  
38  
39  
40 22. Zecca E, Barone G, De Luca D, et al. Skin bilirubin measurement during phototherapy in  
41 preterm and term newborn infants. *Early Hum Dev* 2009;85(8):537-40. doi:  
42 10.1016/j.earlhumdev.2009.05.010 [published Online First: 2009/05/29]  
43  
44  
45  
46  
47 23. Kanti V, Bonzel A, Stroux A, et al. Postnatal maturation of skin barrier function in  
48 premature infants. *Skin Pharmacol Physiol* 2014;27(5):234-41. doi:  
49 10.1159/000354923 [published Online First: 2014/07/26]  
50  
51  
52  
53  
54 24. De Luca D, Dell'Orto V. Patched Skin Bilirubin Assay to Monitor Neonates Born  
55 Extremely Preterm Undergoing Phototherapy. *J Pediatr* 2017;188:122-27. doi:  
56 10.1016/j.jpeds.2017.05.080 [published Online First: 2017/06/26]  
57  
58  
59  
60

Table 1

## Baseline population Characteristics

Variable	Number (n =196)
Male Sex n (%)	105 (53.6%)
Birth Weight (grams) Mean $\pm$ SD	1605 $\pm$ 638
Gestational age (weeks) Mean $\pm$ SD	30.4 $\pm$ 3.2
Mode of Delivery n (%)	
NVD	56 (28.6%)
Instrumental Delivery	3 (1.5%)
Elective LSCS	59 (30.1%)
Emergency LSCS	78 (39.8%)
Apgar score at 1 <sup>st</sup> minute Median (IQR)	7 (5-9)
Apgar score at 5 <sup>th</sup> minute Median (IQR)	9 (8-10)
Blood group infants (when done) n (%)	175 (89%)
A	48 (27.4%)
B	18 (10.2%)
AB	2 (1%)
O	108 (61.7%)
Rhesus +	150/175 (85.7%)
Maternal group n (%)	
A	60 (30.6%)
B	24 (12.2%)
AB	5 (2.6%)
O	104 (53.1%)
Rhesus +	176 (89.9%)
Positive DCT n (%)	7 (3.6%)
Maternal age (years) Mean $\pm$ SD	32 $\pm$ 6.2

NVD, normal vaginal delivery; DCT, direct Coombs test; LSCS, lower segment Caesarean section

**Table 2**  
**Paired samples of TSB and TCB from covered and uncovered skin during phototherapy and post phototherapy**

		Mean $\pm$ SD $\mu\text{mol/l}$	Median (IQR) $\mu\text{mol/l}$	N	P-value
During PT	TCBC	102 $\pm$ 62	102 (55, 146)	299	<0.0001
	TSB	127 $\pm$ 51	124 (89, 162)		
	TCBC - TSB difference	-25 $\pm$ 43	-25 (-49, 1)		
During PT	TCBU	79 $\pm$ 70	61 (18, 127)	309	<0.0001
	TSB	127 $\pm$ 51	122 (86, 162)		
	TCBU - TSB difference	-48 $\pm$ 46	-48 (-79, -18)		
After PT	TCB	143 $\pm$ 63	141 (100, 188)	142	0.0001
	TSB	153 $\pm$ 51	153 (115, 187)		
	TCBC - TSB difference	-10 $\pm$ 31	-13 (-28, 9)		

TSB, total serum bilirubin; TCBC, Transcutaneous bilirubinometry readings from covered skin; TCBU, Transcutaneous bilirubinometry readings from exposed skin; PT, phototherapy; TCB, Transcutaneous bilirubinometry



**Table 3**  
**TCB and TSB pairs 8 and 12 hour post phototherapy**

Hours after PT	N	TSB ( $\mu\text{mol/l}$ ) Mean $\pm$ SD Median (IQR)	TCB ( $\mu\text{mol/l}$ ) Mean $\pm$ SD Median (IQR)	Mean difference (TCB – TSB) ( $\mu\text{mol/l}$ ) Mean $\pm$ SD Median (IQR)	Correlation r (p value)
8 hours	40	133 $\pm$ 51 124 (94, 168)	95 $\pm$ 54 97 (53, 138)	-37 $\pm$ 28 -32 (-49, -22)	0.86 (< 0.0001)
12 hours	36	147 $\pm$ 52 135 (112, 173)	131 $\pm$ 51 123 (95, 154)	-16 $\pm$ 19 -17 (-23, -7)	0.93 (< 0.0001)

TSB, total serum bilirubin; TCB, Transcutaneous bilirubinometry; PT, phototherapy

## Legends

### Figure 1A

Correlation between Total Serum Bilirubin (TSB) and Transcutaneous Bilirubinometry (TCB) from covered skin during phototherapy

### Figure 1B

B–A plot showing the 95% limits of agreement between TCB from covered skin and TSB during phototherapy

### Figure 2A

Correlation between Total Serum Bilirubin (TSB) and Transcutaneous Bilirubinometry (TCB) from uncovered skin during phototherapy

### Figure 2B

B–A plot showing the 95% limits of agreement between TCB from uncovered skin and TSB during phototherapy

### Figure 3A

Correlation between Total Serum Bilirubin (TSB) and Transcutaneous Bilirubinometry (TCB) after phototherapy

### Figure 3B


B–A plot showing the 95% limits of agreement between TCB and TSB after phototherapy

## Appendix 1


1  
2  
3 Phototherapy threshold chart used for infants  $\geq 32$  weeks of gestation (adapted from National  
4  
5 Health Service, Glasgow, UK)  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Confidential: For Review Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




297x210mm (600 x 600 DPI)



297x210mm (600 x 600 DPI)


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



297x210mm (600 x 600 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



338x190mm (300 x 300 DPI)